Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications.

Rowe, R. G. & Daley, G. Q. Induced pluripotent stem cells in disease modelling and drug discovery. Nat. Rev. Genet. 20, 377–388 (2019).

doi: 10.1038/s41576-019-0100-z pubmed: 30737492 pmcid: 6584039

Shi, Y., Inoue, H., Wu, J. C. & Yamanaka, S. Induced pluripotent stem cell technology: a decade of progress. Nat. Rev. Drug Discov. 16, 115–130 (2017).

doi: 10.1038/nrd.2016.245 pubmed: 27980341

Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).

doi: 10.1016/j.cell.2007.11.019 pubmed: 18035408

Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006).

doi: 10.1016/j.cell.2006.07.024 pubmed: 16904174

Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920 (2007).

doi: 10.1126/science.1151526 pubmed: 18029452

Takahashi, K. & Yamanaka, S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat. Rev. Mol. Cell Biol. 17, 183–193 (2016).

doi: 10.1038/nrm.2016.8 pubmed: 26883003

Breschi, A., Gingeras, T. R. & Guigo, R. Comparative transcriptomics in human and mouse. Nat. Rev. Genet. 18, 425–440 (2017).

doi: 10.1038/nrg.2017.19 pubmed: 28479595 pmcid: 6413734

Gharib, W. H. & Robinson-Rechavi, M. When orthologs diverge between human and mouse. Brief. Bioinform. 12, 436–441 (2011).

doi: 10.1093/bib/bbr031 pubmed: 21677033 pmcid: 3178054

Lynch, V. J. Use with caution: developmental systems divergence and potential pitfalls of animal models. Yale J. Biol. Med. 82, 53–66 (2009).

pubmed: 19562005 pmcid: 2701150

Takebe, T. & Wells, J. M. Organoids by design. Science 364, 956–959 (2019).

doi: 10.1126/science.aaw7567 pubmed: 31171692 pmcid: 8212787

Yamanaka, S. Pluripotent Stem Cell-based Cell Therapy- Promise And Challenges. Cell Stem Cell 27, 523–531 (2020).

doi: 10.1016/j.stem.2020.09.014 pubmed: 33007237

Gurdon, J. B. The generation of diversity and pattern in animal development. Cell 68, 185–199 (1992).

doi: 10.1016/0092-8674(92)90465-O pubmed: 1733498

Kiefer, J. C. Epigenetics in development. Dev. Dyn. 236, 1144–1156 (2007).

doi: 10.1002/dvdy.21094 pubmed: 17304537

Tompkins, J. D. Discovering DNA methylation, the history and future of the writing on DNA. J. Hist. Biol. 55, 865–887 (2022).

pubmed: 36239862 pmcid: 9941238

Roe, S. A. Matter, life, and generation: eighteen-century embryology and the Haller-Wolff Debate, (Cambridge University Press, 1981).

Kilgour, F. G. William Harvey and his contributions. Circulation 23, 286–296 (1961).

doi: 10.1161/01.CIR.23.2.286 pubmed: 13755936

Aulie, R. P. Caspar Friedrich Wolff and his ‘Theoria generationis’, 1759. J. Hist. Med. Allied Sci. 16, 124–144 (1961).

doi: 10.1093/jhmas/XVI.2.124 pubmed: 13685148

Weismann, A. Das Keimplasma; eine Theorie der Vererbung, (Jena, Fischer, 1892).

Waddington, C. H. The Strategy of the Genes; A Discussion of Some Aspects of Theoretical Biology, (Cambridge: Cambridge University Press, 1957).

Nanney, D. L. Epigenetic control systems. Proc. Natl. Acad. Sci. USA 44, 712–717 (1958).

doi: 10.1073/pnas.44.7.712 pubmed: 16590265 pmcid: 528649

Gurdon, J. B. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J. Embryol. Exp. Morphol. 10, 622–640 (1962).

pubmed: 13951335

Gurdon, J. B. The transplantation of nuclei between two species of Xenopus. Dev. Biol. 5, 68–83 (1962).

doi: 10.1016/0012-1606(62)90004-0 pubmed: 13903028

Gurdon, J. B. Adult frogs derived from the nuclei of single somatic cells. Dev. Biol. 4, 256–273 (1962).

doi: 10.1016/0012-1606(62)90043-X pubmed: 13903027

Gurdon, J. B. Multiple genetically identical frogs. J. Hered. 53, 5–9 (1962).

doi: 10.1093/oxfordjournals.jhered.a107117 pubmed: 13951336

Gurdon, J. B., Elsdale, T. R. & Fischberg, M. Sexually mature individuals of Xenopus laevis from the transplantation of single somatic nuclei. Nature 182, 64–65 (1958).

doi: 10.1038/182064a0 pubmed: 13566187

Jeltsch, A. & Jurkowska, R. Z. New concepts in DNA methylation. Trends Biochem. Sci. 39, 310–318 (2014).

doi: 10.1016/j.tibs.2014.05.002 pubmed: 24947342

Riggs, A. D. X inactivation, differentiation, and DNA methylation. Cytogenet. Cell Genet. 14, 9–25 (1975).

doi: 10.1159/000130315 pubmed: 1093816

Robertson, K. D. & Wolffe, A. P. DNA methylation in health and disease. Nat. Rev. Genet. 1, 11–19 (2000).

doi: 10.1038/35049533 pubmed: 11262868

Schubeler, D. Function and information content of DNA methylation. Nature 517, 321–326 (2015).

doi: 10.1038/nature14192 pubmed: 25592537

Evans, M. J. & Kaufman, M. H. Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154–156 (1981).

doi: 10.1038/292154a0 pubmed: 7242681

Martin, G. R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. USA 78, 7634–7638 (1981).

doi: 10.1073/pnas.78.12.7634 pubmed: 6950406 pmcid: 349323

Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).

doi: 10.1126/science.282.5391.1145 pubmed: 9804556

Tada, M., Takahama, Y., Abe, K., Nakatsuji, N. & Tada, T. Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. Curr. Biol. 11, 1553–1558 (2001).

doi: 10.1016/S0960-9822(01)00459-6 pubmed: 11591326

Cowan, C. A., Atienza, J., Melton, D. A. & Eggan, K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 309, 1369–1373 (2005).

doi: 10.1126/science.1116447 pubmed: 16123299

Davis, R. L., Weintraub, H. & Lassar, A. B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987–1000 (1987).

doi: 10.1016/0092-8674(87)90585-X pubmed: 3690668

Halder, G., Callaerts, P. & Gehring, W. J. Induction of ectopic eyes by targeted expression of the eyeless gene in drosophila. Science 267, 1788–1792 (1995).

doi: 10.1126/science.7892602 pubmed: 7892602

Kulessa, H., Frampton, J. & Graf, T. Gata-1 reprograms Avian Myelomonocytic cell-lines into Eosinophils, Thromboblasts, and Erythroblasts. Gene Dev. 9, 1250–1262 (1995).

doi: 10.1101/gad.9.10.1250 pubmed: 7758949

Xie, H., Ye, M., Feng, R. & Graf, T. Stepwise reprogramming of B cells into macrophages. Cell 117, 663–676 (2004).

doi: 10.1016/S0092-8674(04)00419-2 pubmed: 15163413

Wernig, M. et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448, 318–324 (2007).

doi: 10.1038/nature05944 pubmed: 17554336

Huangfu, D. W. et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat. Biotechnol. 26, 795–797 (2008).

doi: 10.1038/nbt1418 pubmed: 18568017 pmcid: 6334647

Huangfu, D. et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol. 26, 1269–1275 (2008).

doi: 10.1038/nbt.1502 pubmed: 18849973

Hou, P. et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341, 651–654 (2013).

doi: 10.1126/science.1239278 pubmed: 23868920

Zhu, J. et al. Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell 152, 642–654 (2013).

doi: 10.1016/j.cell.2012.12.033 pubmed: 23333102 pmcid: 3563935

Apostolou, E. & Hochedlinger, K. Chromatin dynamics during cellular reprogramming. Nature 502, 462–471 (2013).

doi: 10.1038/nature12749 pubmed: 24153299 pmcid: 4216318

Apostolou, E. & Stadtfeld, M. Cellular trajectories and molecular mechanisms of iPSC reprogramming. Curr. Opin. Genet. Dev. 52, 77–85 (2018).

doi: 10.1016/j.gde.2018.06.002 pubmed: 29925040 pmcid: 6252123

Cacchiarelli, D. et al. Integrative analyses of human reprogramming reveal dynamic nature of induced pluripotency. Cell 162, 412–424 (2015).

doi: 10.1016/j.cell.2015.06.016 pubmed: 26186193 pmcid: 4511597

Nefzger, C. M. et al. Cell type of origin dictates the route to pluripotency. Cell Rep. 21, 2649–2660 (2017).

doi: 10.1016/j.celrep.2017.11.029 pubmed: 29212013

Borkent, M. et al. A serial shRNA screen for roadblocks to reprogramming identifies the protein modifier SUMO2. Stem Cell Rep. 6, 704–716 (2016).

doi: 10.1016/j.stemcr.2016.02.004

Buckley, S. M. et al. Regulation of Pluripotency and cellular reprogramming by the ubiquitin-proteasome system. Cell Stem Cell 11, 783–798 (2012).

doi: 10.1016/j.stem.2012.09.011 pubmed: 23103054 pmcid: 3549668

Qin, H. et al. Systematic identification of barriers to human iPSC generation. Cell 158, 449–461 (2014).

doi: 10.1016/j.cell.2014.05.040 pubmed: 25036638 pmcid: 4130998

Simic, M. S. et al. Transient activation of the UPR(ER) is an essential step in the acquisition of pluripotency during reprogramming. Sci. Adv. 5, eaaw0025 (2019).

doi: 10.1126/sciadv.aaw0025 pubmed: 30989118 pmcid: 6457941

Wu, Y. et al. Phospholipid remodeling is critical for stem cell pluripotency by facilitating mesenchymal-to-epithelial transition. Sci. Adv. 5, eaax7525 (2019).

doi: 10.1126/sciadv.aax7525 pubmed: 31807705 pmcid: 6881163

Pei, D. Q., Shu, X. D., Gassama-Diagne, A. & Thiery, J. P. Mesenchymal-epithelial transition in development and reprogramming. Nat. Cell Biol. 21, 44–53 (2019).

doi: 10.1038/s41556-018-0195-z pubmed: 30602762

Soufi, A., Donahue, G. & Zaret, K. S. Facilitators and impediments of the pluripotency reprogramming factors’ initial engagement with the genome. Cell 151, 994–1004 (2012).

doi: 10.1016/j.cell.2012.09.045 pubmed: 23159369 pmcid: 3508134

Soufi, A. et al. Pioneer transcription factors target partial DNA Motifs on nucleosomes to initiate reprogramming. Cell 161, 555–568 (2015).

doi: 10.1016/j.cell.2015.03.017 pubmed: 25892221 pmcid: 4409934

Chen, J. et al. Hierarchical Oct4 binding in concert with primed epigenetic rearrangements during somatic cell reprogramming. Cell Rep. 14, 1540–1554 (2016).

doi: 10.1016/j.celrep.2016.01.013 pubmed: 26832419

Chronis, C. et al. Cooperative binding of transcription factors orchestrates reprogramming. Cell 168, 442–459.e420 (2017).

doi: 10.1016/j.cell.2016.12.016 pubmed: 28111071 pmcid: 5302508

Zaret, K. S. & Carroll, J. S. Pioneer transcription factors: establishing competence for gene expression. Gene Dev. 25, 2227–2241 (2011).

doi: 10.1101/gad.176826.111 pubmed: 22056668 pmcid: 3219227

Vanzan, L. et al. High throughput screening identifies SOX2 as a super pioneer factor that inhibits DNA methylation maintenance at its binding sites. Nat. Commun. 12, 3337 (2021).

doi: 10.1038/s41467-021-23630-x pubmed: 34099689 pmcid: 8184831

Roberts, G. A. et al. Dissecting OCT4 defines the role of nucleosome binding in pluripotency. Nat. Cell Biol. 23, 834–845 (2021).

doi: 10.1038/s41556-021-00727-5 pubmed: 34354236 pmcid: 7611526

Di Giammartino, D. C. et al. KLF4 is involved in the organization and regulation of pluripotency-associated three-dimensional enhancer networks. Nat. Cell Biol. 21, 1179–1190 (2019).

doi: 10.1038/s41556-019-0390-6 pubmed: 31548608 pmcid: 7339746

Rahl, P. B. et al. c-Myc regulates transcriptional pause release. Cell 141, 432–445 (2010).

doi: 10.1016/j.cell.2010.03.030 pubmed: 20434984 pmcid: 2864022

Garcia-Gutierrez, L., Delgado, M. D. & Leon, J. MYC oncogene contributions to release of cell cycle brakes. Genes 10, 244 (2019).

doi: 10.3390/genes10030244 pubmed: 30909496 pmcid: 6470592

Smith, Z. D., Sindhu, C. & Meissner, A. Molecular features of cellular reprogramming and development. Nat. Rev. Mol. Cell Biol. 17, 139–154 (2016).

doi: 10.1038/nrm.2016.6 pubmed: 26883001

Deng, W., Jacobson, E. C., Collier, A. J. & Plath, K. The transcription factor code in iPSC reprogramming. Curr. Opin. Genet. Dev. 70, 89–96 (2021).

doi: 10.1016/j.gde.2021.06.003 pubmed: 34246082 pmcid: 9469655

Hernandez, C. et al. Dppa2/4 facilitate epigenetic remodeling during reprogramming to pluripotency. Cell Stem Cell 23, 396–411.e398 (2018).

doi: 10.1016/j.stem.2018.08.001 pubmed: 30146411 pmcid: 6128737

Liu, J. et al. The oncogene c-Jun impedes somatic cell reprogramming. Nat. Cell Biol. 17, 856–867 (2015).

doi: 10.1038/ncb3193 pubmed: 26098572

Markov, G. J. et al. AP-1 is a temporally regulated dual gatekeeper of reprogramming to pluripotency. Proc. Natl. Acad. Sci. USA 118, e2104841118 (2021).

doi: 10.1073/pnas.2104841118 pubmed: 34088849 pmcid: 8201948

Silva, J. et al. Nanog is the gateway to the pluripotent ground state. Cell 138, 722–737 (2009).

doi: 10.1016/j.cell.2009.07.039 pubmed: 19703398 pmcid: 3437554

Nakagawa, M. et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26, 101–106 (2008).

doi: 10.1038/nbt1374 pubmed: 18059259

Mai, T. et al. NKX3-1 is required for induced pluripotent stem cell reprogramming and can replace OCT4 in mouse and human iPSC induction. Nat. Cell Biol. 20, 900–908 (2018).

doi: 10.1038/s41556-018-0136-x pubmed: 30013107 pmcid: 6101038

Kim, J. B. et al. Direct reprogramming of human neural stem cells by OCT4. Nature 461, 649–653 (2009).

doi: 10.1038/nature08436 pubmed: 19718018

Kim, J. B. et al. Oct4-induced pluripotency in adult neural stem cells. Cell 136, 411–419 (2009).

doi: 10.1016/j.cell.2009.01.023 pubmed: 19203577

Radzisheuskaya, A. & Silva, J. C. Do all roads lead to Oct4? the emerging concepts of induced pluripotency. Trends Cell Biol. 24, 275–284 (2014).

doi: 10.1016/j.tcb.2013.11.010 pubmed: 24370212 pmcid: 3976965

Li, D. et al. Chromatin accessibility dynamics during iPSC reprogramming. Cell Stem Cell 21, 819–833.e816 (2017).

doi: 10.1016/j.stem.2017.10.012 pubmed: 29220666

Xing, Q. R. et al. Diversification of reprogramming trajectories revealed by parallel single-cell transcriptome and chromatin accessibility sequencing. Sci. Adv. 6, eaba1190 (2020).

doi: 10.1126/sciadv.aba1190 pubmed: 32917699 pmcid: 7486102

Stadhouders, R. et al. Transcription factors orchestrate dynamic interplay between genome topology and gene regulation during cell reprogramming. Nat. Genet. 50, 238–249 (2018).

doi: 10.1038/s41588-017-0030-7 pubmed: 29335546 pmcid: 5810905

Knaupp, A. S. et al. Transient and permanent reconfiguration of chromatin and transcription factor occupancy drive reprogramming. Cell Stem Cell 21, 834–845.e836 (2017).

doi: 10.1016/j.stem.2017.11.007 pubmed: 29220667

Cheloufi, S. et al. The histone chaperone CAF-1 safeguards somatic cell identity. Nature 528, 218–224 (2015).

doi: 10.1038/nature15749 pubmed: 26659182 pmcid: 4866648

dos Santos, R. L. et al. MBD3/NuRD facilitates induction of pluripotency in a context-dependent manner. Cell Stem Cell 15, 102–110 (2014).

doi: 10.1016/j.stem.2014.04.019 pubmed: 24835571 pmcid: 4082719

Onder, T. T. et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483, 598–602 (2012).

doi: 10.1038/nature10953 pubmed: 22388813 pmcid: 3501145

Chen, J. et al. H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat. Genet. 45, 34–42 (2013).

doi: 10.1038/ng.2491 pubmed: 23202127

Sridharan, R. et al. Proteomic and genomic approaches reveal critical functions of H3K9 methylation and heterochromatin protein-1gamma in reprogramming to pluripotency. Nat. Cell Biol. 15, 872–882 (2013).

doi: 10.1038/ncb2768 pubmed: 23748610 pmcid: 3733997

Li, L. P. et al. Glis1 facilitates induction of pluripotency via an epigenome-metabolome-epigenome signalling cascade (vol 2, pg 882, 2020). Nat. Metab. 2, 1179–1179 (2020).

doi: 10.1038/s42255-020-00308-0 pubmed: 33033400

Tran, K. A. et al. Defining reprogramming checkpoints from single-cell analyses of induced pluripotency. Cell Rep. 27, 1726–1741.e1725 (2019).

doi: 10.1016/j.celrep.2019.04.056 pubmed: 31067459 pmcid: 6555151

Sun, G., Fu, C., Shen, C. & Shi, Y. Histone deacetylases in neural stem cells and induced pluripotent stem cells. J. Biomed. Biotechnol. 2011, 835968 (2011).

doi: 10.1155/2011/835968 pubmed: 21845024 pmcid: 3154389

Yin, Y. et al. Impact of cytosine methylation on DNA binding specificities of human transcription factors. Science 356, eaaj2239 (2017).

doi: 10.1126/science.aaj2239 pubmed: 28473536 pmcid: 8009048

Lyko, F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat. Rev. Genet. 19, 81–92 (2018).

doi: 10.1038/nrg.2017.80 pubmed: 29033456

Pastor, W. A., Aravind, L. & Rao, A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 14, 341–356 (2013).

doi: 10.1038/nrm3589 pubmed: 23698584 pmcid: 3804139

Piccolo, F. M. & Fisher, A. G. Getting rid of DNA methylation. Trends Cell Biol. 24, 136–143 (2014).

doi: 10.1016/j.tcb.2013.09.001 pubmed: 24119665

Rasmussen, K. D. & Helin, K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 30, 733–750 (2016).

doi: 10.1101/gad.276568.115 pubmed: 27036965 pmcid: 4826392

Caldwell, B. A. et al. Functionally distinct roles for TET-oxidized 5-methylcytosine bases in somatic reprogramming to pluripotency. Mol. Cell 81, 859–869.e858 (2021).

doi: 10.1016/j.molcel.2020.11.045 pubmed: 33352108

Doege, C. A. et al. Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 488, 652–655 (2012).

doi: 10.1038/nature11333 pubmed: 22902501 pmcid: 5176099

Sardina, J. L. et al. Transcription factors drive Tet2-mediated enhancer demethylation to reprogram cell fate. Cell Stem Cell 23, 727–741.e729 (2018).

doi: 10.1016/j.stem.2018.08.016 pubmed: 30220521

Zviran, A. et al. Deterministic somatic cell reprogramming involves continuous transcriptional changes governed by Myc and epigenetic-driven modules. Cell Stem Cell 24, 328–341.e329 (2019).

doi: 10.1016/j.stem.2018.11.014 pubmed: 30554962

Hu, X. et al. Tet and TDG mediate DNA demethylation essential for mesenchymal-to-epithelial transition in somatic cell reprogramming. Cell Stem Cell 14, 512–522 (2014).

doi: 10.1016/j.stem.2014.01.001 pubmed: 24529596

Costa, Y. et al. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature 495, 370–374 (2013).

doi: 10.1038/nature11925 pubmed: 23395962 pmcid: 3606645

Gao, Y. W. et al. Replacement of Oct4 by Tet1 during iPSC induction reveals an important role of DNA Methylation and Hydroxymethylation in reprogramming. Cell Stem Cell 12, 453–469 (2013).

doi: 10.1016/j.stem.2013.02.005 pubmed: 23499384

Chen, J. et al. Vitamin C modulates TET1 function during somatic cell reprogramming. Nat. Genet. 45, 1504–1509 (2013).

doi: 10.1038/ng.2807 pubmed: 24162740

Guo, L. et al. Resolving cell fate decisions during somatic cell reprogramming by single-cell RNA-Seq. Mol. Cell 73, 815–829.e817 (2019).

doi: 10.1016/j.molcel.2019.01.042 pubmed: 30772174

Shakiba, N. et al. Cell competition during reprogramming gives rise to dominant clones. Science 364, eaan0925 (2019).

doi: 10.1126/science.aan0925 pubmed: 30898844

Francesconi, M. et al. Single cell RNA-seq identifies the origins of heterogeneity in efficient cell transdifferentiation and reprogramming. Elife 8, e41627 (2019).

doi: 10.7554/eLife.41627 pubmed: 30860479 pmcid: 6435319

Schwarz, B. A. et al. Prospective Isolation of Poised iPSC intermediates reveals principles of cellular reprogramming. Cell Stem Cell 23, 289–305.e285 (2018).

doi: 10.1016/j.stem.2018.06.013 pubmed: 30017590 pmcid: 6086589

Bar-Nur, O., Russ, H. A., Efrat, S. & Benvenisty, N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 9, 17–23 (2011).

doi: 10.1016/j.stem.2011.06.007 pubmed: 21726830

Kim, K. et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat. Biotechnol. 29, 1117–1119 (2011).

doi: 10.1038/nbt.2052 pubmed: 22119740 pmcid: 3357310

Marchetto, M. C. et al. Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS One 4, e7076 (2009).

doi: 10.1371/journal.pone.0007076 pubmed: 19763270 pmcid: 2741600

Ohi, Y. et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat. Cell Biol. 13, 541–549 (2011).

doi: 10.1038/ncb2239 pubmed: 21499256 pmcid: 3987913

Kim, K. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467, 285–290 (2010).

doi: 10.1038/nature09342 pubmed: 20644535 pmcid: 3150836

Rouhani, F. J. et al. Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells. Nat. Genet. 54, 1406–1416 (2022).

doi: 10.1038/s41588-022-01147-3 pubmed: 35953586 pmcid: 9470532

Wei, W., Gaffney, D. J. & Chinnery, P. F. Cell reprogramming shapes the mitochondrial DNA landscape. Nat. Commun. 12, 5241 (2021).

doi: 10.1038/s41467-021-25482-x pubmed: 34475388 pmcid: 8413449

Deuse, T. et al. De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans. Nat. Biotechnol. 37, 1137–1144 (2019).

doi: 10.1038/s41587-019-0227-7 pubmed: 31427818

Narsinh, K. H. et al. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J. Clin. Investig. 121, 1217–1221 (2011).

doi: 10.1172/JCI44635 pubmed: 21317531 pmcid: 3049389

Malik, N. & Rao, M. S. A review of the methods for human iPSC derivation. Methods Mol. Biol. 997, 23–33 (2013).

doi: 10.1007/978-1-62703-348-0_3 pubmed: 23546745 pmcid: 4176696

Manzini, S., Viiri, L. E., Marttila, S. & Aalto-Setala, K. A comparative view on easy to deploy non-integrating methods for patient-specific iPSC production. Stem Cell Rev. Rep. 11, 900–908 (2015).

doi: 10.1007/s12015-015-9619-3 pubmed: 26341105

Scesa, G., Adami, R. & Bottai, D. iPSC preparation and epigenetic memory: does the tissue origin matter? Cells 10, 1470 (2021).

doi: 10.3390/cells10061470 pubmed: 34208270 pmcid: 8230744

Macarthur, C. C. et al. Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions. Stem Cells Int. 2012, 564612 (2012).

doi: 10.1155/2012/564612 pubmed: 22550511 pmcid: 3328201

Seki, T. et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7, 11–14 (2010).

doi: 10.1016/j.stem.2010.06.003 pubmed: 20621043

Zhou, W. B. & Freed, C. R. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 27, 2667–2674 (2009).

doi: 10.1002/stem.201 pubmed: 19697349

Haridhasapavalan, K. K. et al. An insight into non-integrative gene delivery approaches to generate transgene-free induced pluripotent stem cells. Gene 686, 146–159 (2019).

doi: 10.1016/j.gene.2018.11.069 pubmed: 30472380

Kaji, K. et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458, 771–775 (2009).

doi: 10.1038/nature07864 pubmed: 19252477 pmcid: 2667910

Woltjen, K. et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458, 766–770 (2009).

doi: 10.1038/nature07863 pubmed: 19252478 pmcid: 3758996

Chao, J. et al. Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type ASPA gene. iScience 25, 104391 (2022).

doi: 10.1016/j.isci.2022.104391 pubmed: 35637731 pmcid: 9142666

Feng, L. et al. Cell-based therapy for canavan disease using human iPSC-Derived NPCs and OPCs. Adv. Sci. 7, 2002155 (2020).

doi: 10.1002/advs.202002155

Warren, L. et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618–630 (2010).

doi: 10.1016/j.stem.2010.08.012 pubmed: 20888316 pmcid: 3656821

Wen, W. et al. Enhanced generation of integration-free iPSCs from human adult peripheral blood mononuclear cells with an optimal combination of episomal vectors. Stem Cell Rep. 6, 873–884 (2016).

doi: 10.1016/j.stemcr.2016.04.005

Anokye-Danso, F. et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8, 376–388 (2011).

doi: 10.1016/j.stem.2011.03.001 pubmed: 21474102 pmcid: 3090650

Miyoshi, N. et al. Reprogramming of mouse and human cells to pluripotency using mature MicroRNAs. Cell Stem Cell 8, 633–638 (2011).

doi: 10.1016/j.stem.2011.05.001 pubmed: 21620789

Kim, Y., Jeong, J. & Choi, D. Small-molecule-mediated reprogramming: a silver lining for regenerative medicine. Exp. Mol. Med. 52, 213–226 (2020).

doi: 10.1038/s12276-020-0383-3 pubmed: 32080339 pmcid: 7062739

Liuyang, S. et al. Highly efficient and rapid generation of human pluripotent stem cells by chemical reprogramming. Cell Stem Cell 30, 450–459.e459 (2023).

doi: 10.1016/j.stem.2023.02.008 pubmed: 36944335

Guan, J. et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature 605, 325–331 (2022).

doi: 10.1038/s41586-022-04593-5 pubmed: 35418683

Li, W. et al. Identification of Oct4-activating compounds that enhance reprogramming efficiency. Proc. Natl. Acad. Sci. USA 109, 20853–20858 (2012).

doi: 10.1073/pnas.1219181110 pubmed: 23213213 pmcid: 3529047

Zhu, S. et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 7, 651–655 (2010).

doi: 10.1016/j.stem.2010.11.015 pubmed: 21112560

Lin, T. et al. A chemical platform for improved induction of human iPSCs. Nat. Methods 6, 805–808 (2009).

doi: 10.1038/nmeth.1393 pubmed: 19838168 pmcid: 3724527

Cao, S. et al. Chromatin accessibility dynamics during chemical induction of pluripotency. Cell Stem Cell 22, 529–542.e525 (2018).

doi: 10.1016/j.stem.2018.03.005 pubmed: 29625068

Zhao, Y. et al. A XEN-like state bridges somatic cells to pluripotency during chemical reprogramming. Cell 163, 1678–1691 (2015).

doi: 10.1016/j.cell.2015.11.017 pubmed: 26686652

Velychko, S. et al. Excluding Oct4 from Yamanaka cocktail unleashes the developmental potential of iPSCs. Cell Stem Cell 25, 737–753.e734 (2019).

doi: 10.1016/j.stem.2019.10.002 pubmed: 31708402 pmcid: 6900749

Shi, Y. Induced pluripotent stem cells, new tools for drug discovery and new hope for stem cell therapies. Curr. Mol. Pharm. 2, 15–18 (2009).

doi: 10.2174/1874467210902010015

Lo, B. & Parham, L. Ethical issues in stem cell research. Endocr. Rev. 30, 204–213 (2009).

doi: 10.1210/er.2008-0031 pubmed: 19366754 pmcid: 2726839

Robertson, J. A. Human embryonic stem cell research: ethical and legal issues. Nat. Rev. Genet. 2, 74–78 (2001).

doi: 10.1038/35047594 pubmed: 11253076

Fernandopulle, M. S. et al. Transcription factor–mediated differentiation of human iPSCs into neurons. Curr. Protoc. Cell Biol. 79, e51 (2018).

doi: 10.1002/cpcb.51 pubmed: 29924488 pmcid: 6993937

Lin, Y. & Zou, J. Differentiation of cardiomyocytes from human pluripotent stem cells in fully chemically defined conditions. STAR Protoc. 1, 100015 (2020).

doi: 10.1016/j.xpro.2020.100015 pubmed: 32734277 pmcid: 7392178

Iriguchi, S. et al. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. Nat. Commun. 12, 430 (2021).

doi: 10.1038/s41467-020-20658-3 pubmed: 33462228 pmcid: 7814014

Douvaras, P. & Fossati, V. Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells. Nat. Protoc. 10, 1143–1154 (2015).

doi: 10.1038/nprot.2015.075 pubmed: 26134954

Li, L. et al. GFAP mutations in astrocytes impair oligodendrocyte progenitor proliferation and Myelination in an hiPSC model of alexander disease. Cell Stem Cell 23, 239–251.e236 (2018).

doi: 10.1016/j.stem.2018.07.009 pubmed: 30075130 pmcid: 6230521

Wang, S. et al. Human iPSC-derived oligodendrocyte progenitor cells can Myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell 12, 252–264 (2013).

doi: 10.1016/j.stem.2012.12.002 pubmed: 23395447 pmcid: 3700553

Hurley, K. et al. Reconstructed single-cell fate trajectories define lineage plasticity windows during differentiation of human PSC-derived distal lung progenitors. Cell Stem Cell 26, 593–608.e598 (2020).

doi: 10.1016/j.stem.2019.12.009 pubmed: 32004478 pmcid: 7469703

Joung, J. et al. A transcription factor atlas of directed differentiation. Cell 186, 209–229.e226 (2023).

doi: 10.1016/j.cell.2022.11.026 pubmed: 36608654 pmcid: 10344468

Li, Q. V. et al. Genome-scale screens identify JNK-JUN signaling as a barrier for pluripotency exit and endoderm differentiation. Nat. Genet. 51, 999–1010 (2019).

doi: 10.1038/s41588-019-0408-9 pubmed: 31110351 pmcid: 6545159

Washer, S. J. et al. Single-cell transcriptomics defines an improved, validated monoculture protocol for differentiation of human iPSC to microglia. Sci. Rep. 12, 19454 (2022).

doi: 10.1038/s41598-022-23477-2 pubmed: 36376339 pmcid: 9663826

Zheng, H. et al. Generating hematopoietic cells from human pluripotent stem cells: approaches, progress and challenges. Cell Regen. 12, 31 (2023).

doi: 10.1186/s13619-023-00175-6 pubmed: 37656237 pmcid: 10474004

Pratumkaew, P., Issaragrisil, S. & Luanpitpong, S. Induced pluripotent stem cells as a tool for modeling hematologic disorders and as a potential source for cell-based therapies. Cells 10, 3250 (2021).

doi: 10.3390/cells10113250 pubmed: 34831472 pmcid: 8623953

Chambers, S. M. et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27, 275–280 (2009).

doi: 10.1038/nbt.1529 pubmed: 19252484 pmcid: 2756723

Qi, Y. et al. Combined small-molecule inhibition accelerates the derivation of functional cortical neurons from human pluripotent stem cells. Nat. Biotechnol. 35, 154–163 (2017).

doi: 10.1038/nbt.3777 pubmed: 28112759 pmcid: 5516899

Drager, N. M. et al. A CRISPRi/a platform in human iPSC-derived microglia uncovers regulators of disease states. Nat. Neurosci. 25, 1149–1162 (2022).

doi: 10.1038/s41593-022-01131-4 pubmed: 35953545 pmcid: 9448678

Leng, K. et al. CRISPRi screens in human iPSC-derived astrocytes elucidate regulators of distinct inflammatory reactive states. Nat. Neurosci. 25, 1528–1542 (2022).

doi: 10.1038/s41593-022-01180-9 pubmed: 36303069 pmcid: 9633461

Tian, R. et al. Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis. Nat. Neurosci. 24, 1020–1034 (2021).

doi: 10.1038/s41593-021-00862-0 pubmed: 34031600 pmcid: 8254803

Tian, R. et al. CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived neurons. Neuron 104, 239–255.e212 (2019).

doi: 10.1016/j.neuron.2019.07.014 pubmed: 31422865 pmcid: 6813890

Guttikonda, S. R. et al. Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in Alzheimer’s disease. Nat. Neurosci. 24, 343–354 (2021).

doi: 10.1038/s41593-020-00796-z pubmed: 33558694 pmcid: 8382543

Park, J. et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease. Nat. Neurosci. 21, 941–951 (2018).

doi: 10.1038/s41593-018-0175-4 pubmed: 29950669 pmcid: 6800152

Kim, J., Koo, B. K. & Knoblich, J. A. Human organoids: model systems for human biology and medicine. Nat. Rev. Mol. Cell Biol. 21, 571–584 (2020).

doi: 10.1038/s41580-020-0259-3 pubmed: 32636524 pmcid: 7339799

Schutgens, F. & Clevers, H. Human organoids: tools for understanding biology and treating diseases. Annu Rev. Pathol. 15, 211–234 (2020).

doi: 10.1146/annurev-pathmechdis-012419-032611 pubmed: 31550983

Hofer, M. & Lutolf, M. P. Engineering organoids. Nat. Rev. Mater. 6, 402–420 (2021).

doi: 10.1038/s41578-021-00279-y pubmed: 33623712 pmcid: 7893133

Corsini, N. S. & Knoblich, J. A. Human organoids: new strategies and methods for analyzing human development and disease. Cell 185, 2756–2769 (2022).

doi: 10.1016/j.cell.2022.06.051 pubmed: 35868278

Rossi, G., Manfrin, A. & Lutolf, M. P. Progress and potential in organoid research. Nat. Rev. Genet. 19, 671–687 (2018).

doi: 10.1038/s41576-018-0051-9 pubmed: 30228295

Cederquist, G. Y. et al. Specification of positional identity in forebrain organoids. Nat. Biotechnol. 37, 436–444 (2019).

doi: 10.1038/s41587-019-0085-3 pubmed: 30936566 pmcid: 6447454

Morizane, R. et al. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat. Biotechnol. 33, 1193–1200 (2015).

doi: 10.1038/nbt.3392 pubmed: 26458176 pmcid: 4747858

Bershteyn, M. et al. Human iPSC-derived cerebral organoids model cellular features of lissencephaly and reveal prolonged mitosis of outer radial Glia. Cell Stem Cell 20, 435–449.e434 (2017).

doi: 10.1016/j.stem.2016.12.007 pubmed: 28111201 pmcid: 5667944

Qian, X. et al. Sliced human cortical organoids for modeling distinct cortical layer formation. Cell Stem Cell 26, 766–781.e769 (2020).

doi: 10.1016/j.stem.2020.02.002 pubmed: 32142682 pmcid: 7366517

Abbott, J. et al. Generation and characterization of NGLY1 patient-derived midbrain organoids. Front Cell Dev. Biol. 11, 1039182 (2023).

doi: 10.3389/fcell.2023.1039182 pubmed: 36875753 pmcid: 9978932

Sabate-Soler, S. et al. Microglia integration into human midbrain organoids leads to increased neuronal maturation and functionality. Glia 70, 1267–1288 (2022).

doi: 10.1002/glia.24167 pubmed: 35262217 pmcid: 9314680

Jacob, F. et al. Human pluripotent stem cell-derived neural cells and brain organoids reveal SARS-CoV-2 neurotropism predominates in choroid plexus epithelium. Cell Stem Cell 27, 937–950.e939 (2020).

doi: 10.1016/j.stem.2020.09.016 pubmed: 33010822 pmcid: 7505550

Ballabio, C. et al. Modeling medulloblastoma in vivo and with human cerebellar organoids. Nat. Commun. 11, 583 (2020).

doi: 10.1038/s41467-019-13989-3 pubmed: 31996670 pmcid: 6989674

van Essen, M. J. et al. PTCH1-mutant human cerebellar organoids exhibit altered neural development and recapitulate early medulloblastoma tumorigenesis. Dis. Model Mech. 17, dmm050323 (2024).

Gabriel, E. et al. Human brain organoids assemble functionally integrated bilateral optic vesicles. Cell Stem Cell 28, 1740–1757.e1748 (2021).

doi: 10.1016/j.stem.2021.07.010 pubmed: 34407456

Gagliardi, G. et al. Characterization and transplantation of CD73-positive photoreceptors isolated from human iPSC-derived retinal organoids. Stem Cell Rep. 11, 665–680 (2018).

doi: 10.1016/j.stemcr.2018.07.005

Lane, A. et al. Modeling and rescue of RP2 Retinitis Pigmentosa using iPSC-derived retinal organoids. Stem Cell Rep. 15, 67–79 (2020).

doi: 10.1016/j.stemcr.2020.05.007

Del Dosso, A., Urenda, J. P., Nguyen, T. & Quadrato, G. Upgrading the physiological relevance of human brain organoids. Neuron 107, 1014–1028 (2020).

doi: 10.1016/j.neuron.2020.08.029 pubmed: 32970996 pmcid: 10042151

Di Lullo, E. & Kriegstein, A. R. The use of brain organoids to investigate neural development and disease. Nat. Rev. Neurosci. 18, 573–584 (2017).

doi: 10.1038/nrn.2017.107 pubmed: 28878372 pmcid: 5667942

Cerneckis, J. & Shi, Y. Myelin organoids for the study of Alzheimer’s disease. Front. Neurosci. 17, 1283742 (2023).

doi: 10.3389/fnins.2023.1283742 pubmed: 37942133 pmcid: 10628225

Feng, L. et al. Developing a human iPSC-derived three-dimensional myelin spheroid platform for modeling myelin diseases. iScience 26, 108037 (2023).

doi: 10.1016/j.isci.2023.108037 pubmed: 37867939 pmcid: 10589867

Broda, T. R., McCracken, K. W. & Wells, J. M. Generation of human antral and fundic gastric organoids from pluripotent stem cells. Nat. Protoc. 14, 28–50 (2019).

doi: 10.1038/s41596-018-0080-z pubmed: 30470820 pmcid: 7951181

McCracken, K. W. et al. Wnt/beta-catenin promotes gastric fundus specification in mice and humans. Nature 541, 182–187 (2017).

doi: 10.1038/nature21021 pubmed: 28052057 pmcid: 5526592

Kanton, S. & Pasca, S. P. Human assembloids. Development 149, dev201120 (2022).

doi: 10.1242/dev.201120 pubmed: 36317797

Pasca, S. P. Assembling human brain organoids. Science 363, 126–127 (2019).

doi: 10.1126/science.aau5729 pubmed: 30630918

Pasca, S. P. et al. A nomenclature consensus for nervous system organoids and assembloids. Nature 609, 907–910 (2022).

doi: 10.1038/s41586-022-05219-6 pubmed: 36171373 pmcid: 10571504

Martins, J. M. F. et al. Self-organizing 3D human trunk neuromuscular organoids. Cell Stem Cell 26, 172–186.e176 (2020).

doi: 10.1016/j.stem.2019.12.007

Andersen, J. et al. Generation of functional Human 3D Cortico-Motor Assembloids. Cell 183, 1913–1929.e1926 (2020).

doi: 10.1016/j.cell.2020.11.017 pubmed: 33333020 pmcid: 8711252

Leung, C. M. et al. A guide to the organ-on-a-chip. Nat. Rev. Methods Prim. 2, 33 (2022).

doi: 10.1038/s43586-022-00118-6

Ma, C., Peng, Y., Li, H. & Chen, W. Organ-on-a-Chip: a new paradigm for drug development. Trends Pharm. Sci. 42, 119–133 (2021).

doi: 10.1016/j.tips.2020.11.009 pubmed: 33341248

Wu, Q. et al. Organ-on-a-chip: recent breakthroughs and future prospects. Biomed. Eng. Online 19, 1–9 (2020).

doi: 10.1186/s12938-020-0752-0

Zhang, B. Y., Korolj, A., Lai, B. F. L. & Radisic, M. Advances in organ-on-a-chip engineering. Nat. Rev. Mater. 3, 257–278 (2018).

doi: 10.1038/s41578-018-0034-7

Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P. & Tagle, D. A. Organs-on-chips: into the next decade. Nat. Rev. Drug Discov. 20, 345–361 (2021).

doi: 10.1038/s41573-020-0079-3 pubmed: 32913334

Tavakol, D. N., Fleischer, S. & Vunjak-Novakovic, G. Harnessing organs-on-a-chip to model tissue regeneration. Cell Stem Cell 28, 993–1015 (2021).

doi: 10.1016/j.stem.2021.05.008 pubmed: 34087161 pmcid: 8186820

Vunjak-Novakovic, G., Ronaldson-Bouchard, K. & Radisic, M. Organs-on-a-chip models for biological research. Cell 184, 4597–4611 (2021).

doi: 10.1016/j.cell.2021.08.005 pubmed: 34478657 pmcid: 8417425

van der Helm, M. W., van der Meer, A. D., Eijkel, J. C., van den Berg, A. & Segerink, L. I. Microfluidic organ-on-chip technology for blood-brain barrier research. Tissue Barriers 4, e1142493 (2016).

doi: 10.1080/21688370.2016.1142493 pubmed: 27141422 pmcid: 4836466

Zakharova, M. et al. Multiplexed blood-brain barrier organ-on-chip. Lab Chip 20, 3132–3143 (2020).

doi: 10.1039/D0LC00399A pubmed: 32756644

Sone, N. et al. Multicellular modeling of ciliopathy by combining iPS cells and microfluidic airway-on-a-chip technology. Sci. Transl. Med 13, eabb1298 (2021).

doi: 10.1126/scitranslmed.abb1298 pubmed: 34233948

Vatine, G. D. et al. Human iPSC-derived blood-brain barrier chips enable disease modeling and personalized medicine applications. Cell Stem Cell 24, 995–1005.e1006 (2019).

doi: 10.1016/j.stem.2019.05.011 pubmed: 31173718

Michas, C. et al. Engineering a living cardiac pump on a chip using high-precision fabrication. Sci. Adv. 8, eabm3791 (2022).

doi: 10.1126/sciadv.abm3791 pubmed: 35452278 pmcid: 9032966

Zhao, Y. et al. A platform for generation of chamber-specific cardiac tissues and disease modeling. Cell 176, 913–927.e918 (2019).

doi: 10.1016/j.cell.2018.11.042 pubmed: 30686581 pmcid: 6456036

Shultz, L. D. et al. Humanized mouse models of immunological diseases and precision medicine. Mamm. Genome 30, 123–142 (2019).

doi: 10.1007/s00335-019-09796-2 pubmed: 30847553 pmcid: 6610695

Flahou, C., Morishima, T., Takizawa, H. & Sugimoto, N. Fit-for-all iPSC-derived cell therapies and their evaluation in humanized mice with NK cell immunity. Front. Immunol. 12, 662360 (2021).

doi: 10.3389/fimmu.2021.662360 pubmed: 33897711 pmcid: 8059435

Moquin-Beaudry, G. et al. Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions. Cell Rep. Methods 2, 100153 (2022).

doi: 10.1016/j.crmeth.2021.100153 pubmed: 35474871 pmcid: 9017190

Zeleniak, A. et al. De novo construction of T cell compartment in humanized mice engrafted with iPSC-derived thymus organoids. Nat. Methods 19, 1306–1319 (2022).

doi: 10.1038/s41592-022-01583-3 pubmed: 36064772

Sharma, A., Sances, S., Workman, M. J. & Svendsen, C. N. Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery. Cell Stem Cell 26, 309–329 (2020).

doi: 10.1016/j.stem.2020.02.011 pubmed: 32142662 pmcid: 7159985

Abud, E. M. et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron 94, 278–293.e279 (2017).

doi: 10.1016/j.neuron.2017.03.042 pubmed: 28426964 pmcid: 5482419

Fattorelli, N. et al. Stem-cell-derived human microglia transplanted into mouse brain to study human disease. Nat. Protoc. 16, 1013–1033 (2021).

doi: 10.1038/s41596-020-00447-4 pubmed: 33424025

Hasselmann, J. et al. Development of a chimeric model to study and manipulate human microglia in vivo. Neuron 103, 1016–1033.e1010 (2019).

doi: 10.1016/j.neuron.2019.07.002 pubmed: 31375314 pmcid: 7138101

Svoboda, D. S. et al. Human iPSC-derived microglia assume a primary microglia-like state after transplantation into the neonatal mouse brain. Proc. Natl. Acad. Sci. USA 116, 25293–25303 (2019).

doi: 10.1073/pnas.1913541116 pubmed: 31772018 pmcid: 6911218

Xu, R. et al. Human iPSC-derived mature microglia retain their identity and functionally integrate in the chimeric mouse brain. Nat. Commun. 11, 1577 (2020).

doi: 10.1038/s41467-020-15411-9 pubmed: 32221280 pmcid: 7101330

Wimmer, R. A. et al. Human blood vessel organoids as a model of diabetic vasculopathy. Nature 565, 505–510 (2019).

doi: 10.1038/s41586-018-0858-8 pubmed: 30651639 pmcid: 7116578

Ho, R. et al. ALS disrupts spinal motor neuron maturation and aging pathways within gene co-expression networks. Nat. Neurosci. 19, 1256–1267 (2016).

doi: 10.1038/nn.4345 pubmed: 27428653 pmcid: 5003654

Alvarez, Z. et al. Artificial extracellular matrix scaffolds of mobile molecules enhance maturation of human stem cell-derived neurons. Cell Stem Cell 30, 219–238.e214 (2023).

doi: 10.1016/j.stem.2022.12.010 pubmed: 36638801

Yoshida, S. et al. Maturation of human induced pluripotent stem cell-derived cardiomyocytes by soluble factors from human mesenchymal stem cells. Mol. Ther. 26, 2681–2695 (2018).

doi: 10.1016/j.ymthe.2018.08.012 pubmed: 30217728 pmcid: 6224789

Giacomelli, E. et al. Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease. Cell Stem Cell 26, 862–879.e811 (2020).

doi: 10.1016/j.stem.2020.05.004 pubmed: 32459996 pmcid: 7284308

Maoz, B. M. et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells. Nat. Biotechnol. 36, 865–874 (2018).

doi: 10.1038/nbt.4226 pubmed: 30125269 pmcid: 9254231

Hayashi, R. et al. Generation of 3D lacrimal gland organoids from human pluripotent stem cells. Nature 605, 126–131 (2022).

doi: 10.1038/s41586-022-04613-4 pubmed: 35444274

Mansour, A. A. et al. An in vivo model of functional and vascularized human brain organoids. Nat. Biotechnol. 36, 432–441 (2018).

doi: 10.1038/nbt.4127 pubmed: 29658944 pmcid: 6331203

Munera, J. O. et al. Differentiation of human pluripotent stem cells into colonic organoids via transient activation of BMP signaling. Cell Stem Cell 21, 51–64.e56 (2017).

doi: 10.1016/j.stem.2017.05.020 pubmed: 28648364 pmcid: 5531599

Revah, O. et al. Maturation and circuit integration of transplanted human cortical organoids. Nature 610, 319–326 (2022).

doi: 10.1038/s41586-022-05277-w pubmed: 36224417 pmcid: 9556304

Tanaka, J. et al. Human induced pluripotent stem cell-derived salivary gland organoids model SARS-CoV-2 infection and replication. Nat. Cell Biol. 24, 1595–1605 (2022).

doi: 10.1038/s41556-022-01007-6 pubmed: 36253535

Schafer, S. T. et al. An in vivo neuroimmune organoid model to study human microglia phenotypes. Cell 186, 2111–2126.e2120 (2023).

doi: 10.1016/j.cell.2023.04.022 pubmed: 37172564

Cerneckis, J. & Shi, Y. Context matters: hPSC-derived microglia thrive in a humanized brain environment in vivo. Cell Stem Cell 30, 909–910 (2023).

doi: 10.1016/j.stem.2023.05.013 pubmed: 37419102 pmcid: 10505011

Ronaldson-Bouchard, K. et al. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature 556, 239–243 (2018).

doi: 10.1038/s41586-018-0016-3 pubmed: 29618819 pmcid: 5895513

Tu, C. Y., Chao, B. S. & Wu, J. C. Strategies for improving the maturity of human induced pluripotent stem cell-derived cardiomyocytes. Circ. Res. 123, 512–514 (2018).

doi: 10.1161/CIRCRESAHA.118.313472 pubmed: 30355143 pmcid: 6392006

Luo, J. et al. Tissue-engineered vascular grafts with advanced mechanical strength from human iPSCs. Cell Stem Cell 26, 251–261.e258 (2020).

doi: 10.1016/j.stem.2019.12.012 pubmed: 31956039 pmcid: 7021512

Ronaldson-Bouchard, K. et al. Engineering of human cardiac muscle electromechanically matured to an adult-like phenotype. Nat. Protoc. 14, 2781–2817 (2019).

doi: 10.1038/s41596-019-0189-8 pubmed: 31492957 pmcid: 7195192

Shin, D. et al. Thalamocortical organoids enable in vitro modeling of 22q11.2 microdeletion associated with neuropsychiatric disorders. Cell Stem Cell 31, 421–432.e428 (2024).

doi: 10.1016/j.stem.2024.01.010 pubmed: 38382530

Regev, A. et al. The Human Cell Atlas. Elife 6, e27041 (2017).

Rozenblatt-Rosen, O., Stubbington, M. J. T., Regev, A. & Teichmann, S. A. The human cell atlas: from vision to reality. Nature 550, 451–453 (2017).

doi: 10.1038/550451a pubmed: 29072289

Zheng, Y. et al. Controlled modelling of human epiblast and amnion development using stem cells. Nature 573, 421–425 (2019).

doi: 10.1038/s41586-019-1535-2 pubmed: 31511693 pmcid: 8106232

Sasaki, K. et al. Robust In vitro induction of human germ cell fate from pluripotent stem cells. Cell Stem Cell 17, 178–194 (2015).

doi: 10.1016/j.stem.2015.06.014 pubmed: 26189426

Hayashi, M., Kawaguchi, T., Durcova-Hills, G. & Imai, H. Generation of germ cells from pluripotent stem cells in mammals. Reprod. Med. Biol. 17, 107–114 (2018).

doi: 10.1002/rmb2.12077 pubmed: 29692667

Esfahani, S. N. et al. Derivation of human primordial germ cell-like cells in an embryonic-like culture. Nat. Commun. 15, 167 (2024).

doi: 10.1038/s41467-023-43871-2 pubmed: 38167821 pmcid: 10762101

Matsuda, M. et al. Recapitulating the human segmentation clock with pluripotent stem cells. Nature 580, 124–129 (2020).

doi: 10.1038/s41586-020-2144-9 pubmed: 32238941

Weatherbee, B. A. T. et al. Pluripotent stem cell-derived model of the post-implantation human embryo. Nature 622, 584–593 (2023).

doi: 10.1038/s41586-023-06368-y pubmed: 37369347 pmcid: 10584688

Zernicka-Goetz, M. The evolution of embryo models. Nat. Methods 20, 1844–1848 (2023).

doi: 10.1038/s41592-023-02077-6 pubmed: 38057512

Manor, Y. S., Massarwa, R. & Hanna, J. H. Establishing the human naive pluripotent state. Curr. Opin. Genet. Dev. 34, 35–45 (2015).

doi: 10.1016/j.gde.2015.07.005 pubmed: 26291026

Weinberger, L., Ayyash, M., Novershtern, N. & Hanna, J. H. Dynamic stem cell states: naive to primed pluripotency in rodents and humans. Nat. Rev. Mol. Cell Biol. 17, 155–169 (2016).

doi: 10.1038/nrm.2015.28 pubmed: 26860365

Zhou, J., Hu, J., Wang, Y. & Gao, S. Induction and application of human naive pluripotency. Cell Rep. 42, 112379 (2023).

doi: 10.1016/j.celrep.2023.112379 pubmed: 37043354

Giulitti, S. et al. Direct generation of human naive induced pluripotent stem cells from somatic cells in microfluidics. Nat. Cell Biol. 21, 275–286 (2019).

doi: 10.1038/s41556-018-0254-5 pubmed: 30598530

Li, W. et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4, 16–19 (2009).

doi: 10.1016/j.stem.2008.11.014 pubmed: 19097958

Sahakyan, A. et al. Human naive pluripotent stem cells Model X chromosome dampening and X inactivation. Cell Stem Cell 20, 87–101 (2017).

doi: 10.1016/j.stem.2016.10.006 pubmed: 27989770

Theunissen, T. W. et al. Molecular criteria for defining the naive human pluripotent state. Cell Stem Cell 19, 502–515 (2016).

doi: 10.1016/j.stem.2016.06.011 pubmed: 27424783 pmcid: 5065525

Kagawa, H. et al. Human blastoids model blastocyst development and implantation. Nature 601, 600–605 (2022).

doi: 10.1038/s41586-021-04267-8 pubmed: 34856602

Wei, Y. et al. Efficient derivation of human trophoblast stem cells from primed pluripotent stem cells. Sci. Adv. 7, eabf4416 (2021).

doi: 10.1126/sciadv.abf4416 pubmed: 34380613 pmcid: 8357231

Castel, G. et al. Induction of human trophoblast stem cells from somatic cells and pluripotent stem cells. Cell Rep. 33, 108419 (2020).

doi: 10.1016/j.celrep.2020.108419 pubmed: 33238118

Jang, Y. J., Kim, M., Lee, B. K. & Kim, J. Induction of human trophoblast stem-like cells from primed pluripotent stem cells. Proc. Natl. Acad. Sci. USA 119, e2115709119 (2022).

doi: 10.1073/pnas.2115709119 pubmed: 35537047 pmcid: 9171790

Earley, A. M., Burbulla, L. F., Krainc, D. & Awatramani, R. Identification of ASCL1 as a determinant for human iPSC-derived dopaminergic neurons. Sci. Rep. 11, 22257 (2021).

doi: 10.1038/s41598-021-01366-4 pubmed: 34782629 pmcid: 8593045

Jerber, J. et al. Population-scale single-cell RNA-seq profiling across dopaminergic neuron differentiation. Nat. Genet. 53, 304–312 (2021).

doi: 10.1038/s41588-021-00801-6 pubmed: 33664506 pmcid: 7610897

Camp, J. G. et al. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proc. Natl. Acad. Sci. USA 112, 15672–15677 (2015).

doi: 10.1073/pnas.1520760112 pubmed: 26644564 pmcid: 4697386

Fleck, J. S. et al. Inferring and perturbing cell fate regulomes in human brain organoids. Nature 621, 365–372 (2023).

doi: 10.1038/s41586-022-05279-8 pubmed: 36198796

Lee, J. H. et al. Production of human spinal-cord organoids recapitulating neural-tube morphogenesis. Nat. Biomed. Eng. 6, 435–448 (2022).

doi: 10.1038/s41551-022-00868-4 pubmed: 35347276

Hofbauer, P. et al. Cardioids reveal self-organizing principles of human cardiogenesis. Cell 184, 3299–3317.e3222 (2021).

doi: 10.1016/j.cell.2021.04.034 pubmed: 34019794

Marton, R. M. & Pasca, S. P. Organoid and assembloid technologies for investigating cellular crosstalk in human brain development and disease. Trends Cell Biol. 30, 133–143 (2020).

doi: 10.1016/j.tcb.2019.11.004 pubmed: 31879153

Koike, H. et al. Modelling human hepato-biliary-pancreatic organogenesis from the foregut-midgut boundary. Nature 574, 112–116 (2019).

doi: 10.1038/s41586-019-1598-0 pubmed: 31554966 pmcid: 7643931

Miura, Y. et al. Generation of human striatal organoids and cortico-striatal assembloids from human pluripotent stem cells. Nat. Biotechnol. 38, 1421–1430 (2020).

doi: 10.1038/s41587-020-00763-w pubmed: 33273741 pmcid: 9042317

Xiang, Y. et al. Fusion of regionally specified hPSC-derived organoids models human brain development and interneuron migration. Cell Stem Cell 21, 383–398.e387 (2017).

doi: 10.1016/j.stem.2017.07.007 pubmed: 28757360 pmcid: 5720381

Soldner, F. & Jaenisch, R. iPSC disease modeling. Science 338, 1155–1156 (2012).

doi: 10.1126/science.1227682 pubmed: 23197518

Li, L., Chao, J. & Shi, Y. Modeling neurological diseases using iPSC-derived neural cells : iPSC modeling of neurological diseases. Cell Tissue Res. 371, 143–151 (2018).

doi: 10.1007/s00441-017-2713-x pubmed: 29079884

Israel, M. A. et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature 482, 216–220 (2012).

doi: 10.1038/nature10821 pubmed: 22278060 pmcid: 3338985

Kwart, D. et al. A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP beta-CTFs, Not Abeta. Neuron 104, 256–270.e255 (2019).

doi: 10.1016/j.neuron.2019.07.010 pubmed: 31416668

Liu, Q. et al. Effect of potent gamma-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol. 71, 1481–1489 (2014).

doi: 10.1001/jamaneurol.2014.2482 pubmed: 25285942 pmcid: 4374637

Hendriks, D., Clevers, H. & Artegiani, B. CRISPR-Cas tools and their application in genetic engineering of human stem cells and organoids. Cell Stem Cell 27, 705–731 (2020).

doi: 10.1016/j.stem.2020.10.014 pubmed: 33157047

Firth, A. L. et al. Functional gene correction for cystic fibrosis in lung epithelial cells generated from patient iPSCs. Cell Rep. 12, 1385–1390 (2015).

doi: 10.1016/j.celrep.2015.07.062 pubmed: 26299960 pmcid: 4559351

Lin, Y. T. et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron 98, 1294–1294 (2018).

doi: 10.1016/j.neuron.2018.06.011 pubmed: 29953873 pmcid: 6048952

Liu, Z. et al. Astrocytic response mediated by the CLU risk allele inhibits OPC proliferation and myelination in a human iPSC model. Cell Rep. 42, 112841 (2023).

doi: 10.1016/j.celrep.2023.112841 pubmed: 37494190 pmcid: 10510531

Brunner, J. W. et al. Power and optimal study design in iPSC-based brain disease modelling. Mol. Psychiatry 28, 1545–1556 (2023).

doi: 10.1038/s41380-022-01866-3 pubmed: 36385170

Kondo, T. et al. Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients. Nat. Aging 2, 125–139 (2022).

doi: 10.1038/s43587-021-00158-9 pubmed: 37117761

Kimura, M. et al. En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH. Cell 185, 4216–4232.e4216 (2022).

doi: 10.1016/j.cell.2022.09.031 pubmed: 36240780 pmcid: 9617783

Park, J. C. et al. A logical network-based drug-screening platform for Alzheimer’s disease representing pathological features of human brain organoids. Nat. Commun. 12, 280 (2021).

doi: 10.1038/s41467-020-20440-5 pubmed: 33436582 pmcid: 7804132

Parenti, I., Rabaneda, L. G., Schoen, H. & Novarino, G. Neurodevelopmental disorders: from genetics to functional pathways. Trends Neurosci. 43, 608–621 (2020).

doi: 10.1016/j.tins.2020.05.004 pubmed: 32507511

Thapar, A., Cooper, M. & Rutter, M. Neurodevelopmental disorders. Lancet Psychiatry 4, 339–346 (2017).

doi: 10.1016/S2215-0366(16)30376-5 pubmed: 27979720

Fang, R. et al. Conservation and divergence of cortical cell organization in human and mouse revealed by MERFISH. Science 377, 56–62 (2022).

doi: 10.1126/science.abm1741 pubmed: 35771910 pmcid: 9262715

Hodge, R. D. et al. Conserved cell types with divergent features in human versus mouse cortex. Nature 573, 61–68 (2019).

doi: 10.1038/s41586-019-1506-7 pubmed: 31435019 pmcid: 6919571

Pembroke, W. G., Hartl, C. L. & Geschwind, D. H. Evolutionary conservation and divergence of the human brain transcriptome. Genome Biol. 22, 1–33 (2021).

doi: 10.1186/s13059-020-02257-z

Zhu, Y. et al. Spatiotemporal transcriptomic divergence across human and macaque brain development. Science 362, eaat8077 (2018).

doi: 10.1126/science.aat8077 pubmed: 30545855 pmcid: 6900982

Li, L. & Shi, Y. When glia meet induced pluripotent stem cells (iPSCs). Mol. Cell Neurosci. 109, 103565 (2020).

doi: 10.1016/j.mcn.2020.103565 pubmed: 33068719 pmcid: 10506562

Shao, Z. et al. Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophrenia. Nat. Neurosci. 22, 229–242 (2019).

doi: 10.1038/s41593-018-0313-z pubmed: 30664768 pmcid: 6373728

Szabo, A. et al. A human iPSC-astroglia neurodevelopmental model reveals divergent transcriptomic patterns in schizophrenia. Transl. Psychiatry 11, 554 (2021).

doi: 10.1038/s41398-021-01681-4 pubmed: 34716291 pmcid: 8556332

Topol, A. et al. Dysregulation of miRNA-9 in a subset of schizophrenia patient-derived neural progenitor cells. Cell Rep. 15, 1024–1036 (2016).

doi: 10.1016/j.celrep.2016.03.090 pubmed: 27117414 pmcid: 4856588

Yoon, K. J. et al. Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity. Cell Stem Cell 15, 79–91 (2014).

doi: 10.1016/j.stem.2014.05.003 pubmed: 24996170 pmcid: 4237009

Murai, K. et al. The TLX-miR-219 cascade regulates neural stem cell proliferation in neurodevelopment and schizophrenia iPSC model. Nat. Commun. 7, 10965 (2016).

doi: 10.1038/ncomms10965 pubmed: 26965827 pmcid: 4793043

Schafer, S. T. et al. Pathological priming causes developmental gene network heterochronicity in autistic subject-derived neurons. Nat. Neurosci. 22, 243–255 (2019).

doi: 10.1038/s41593-018-0295-x pubmed: 30617258 pmcid: 6402576

Wang, M. et al. Increased neural progenitor proliferation in a hiPSC model of autism induces replication stress-associated genome instability. Cell Stem Cell 26, 221–233.e226 (2020).

doi: 10.1016/j.stem.2019.12.013 pubmed: 32004479 pmcid: 7175642

Kathuria, A. et al. Synaptic deficits in iPSC-derived cortical interneurons in schizophrenia are mediated by NLGN2 and rescued by N-acetylcysteine. Transl. Psychiatry 9, 321 (2019).

doi: 10.1038/s41398-019-0660-x pubmed: 31780643 pmcid: 6882825

Kizner, V., Fischer, S. & Naujock, M. Multielectrode Array (MEA)-based detection of spontaneous network activity in human iPSC-derived cortical neurons. Methods Mol. Biol. 1994, 209–216 (2019).

doi: 10.1007/978-1-4939-9477-9_19 pubmed: 31124118

Sun, G. et al. Modeling human cytomegalovirus-induced microcephaly in human iPSC-derived brain organoids. Cell Rep. Med. 1, 100002 (2020).

doi: 10.1016/j.xcrm.2020.100002 pubmed: 33205055 pmcid: 7659592

Brennand, K. J. et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221–225 (2011).

doi: 10.1038/nature09915 pubmed: 21490598 pmcid: 3392969

Wen, Z. et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature 515, 414–418 (2014).

doi: 10.1038/nature13716 pubmed: 25132547 pmcid: 4501856

Zaslavsky, K. et al. SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons. Nat. Neurosci. 22, 556–564 (2019).

doi: 10.1038/s41593-019-0365-8 pubmed: 30911184 pmcid: 6475597

Cai, H. W. et al. Brain organoid reservoir computing for artificial intelligence. Nat. Electron 6, 1032–1039 (2023).

doi: 10.1038/s41928-023-01069-w

Kagan, B. J. et al. In vitro neurons learn and exhibit sentience when embodied in a simulated game-world. Neuron 110, 3952–3969.e3958 (2022).

doi: 10.1016/j.neuron.2022.09.001 pubmed: 36228614 pmcid: 9747182

Chiaradia, I. & Lancaster, M. A. Brain organoids for the study of human neurobiology at the interface of in vitro and in vivo. Nat. Neurosci. 23, 1496–1508 (2020).

doi: 10.1038/s41593-020-00730-3 pubmed: 33139941

Wang, H. Modeling neurological diseases with human brain organoids. Front. Synaptic Neurosci. 10, 15 (2018).

doi: 10.3389/fnsyn.2018.00015 pubmed: 29937727 pmcid: 6002496

Velasco, S., Paulsen, B. & Arlotta, P. 3D brain organoids: studying brain development and disease outside the embryo. Annu Rev. Neurosci. 43, 375–389 (2020).

doi: 10.1146/annurev-neuro-070918-050154 pubmed: 32640930

Cerneckis, J. & Shi, Y. Modeling brain macrophage biology and neurodegenerative diseases using human iPSC-derived neuroimmune organoids. Front. Cell Neurosci. 17, 1198715 (2023).

doi: 10.3389/fncel.2023.1198715 pubmed: 37342768 pmcid: 10277621

Mariani, J. et al. FOXG1-dependent dysregulation of GABA/Glutamate neuron differentiation in autism spectrum disorders. Cell 162, 375–390 (2015).

doi: 10.1016/j.cell.2015.06.034 pubmed: 26186191 pmcid: 4519016

Xu, R. et al. OLIG2 drives abnormal neurodevelopmental phenotypes in human iPSC-based organoid and chimeric mouse models of down syndrome. Cell Stem Cell 24, 908–926.e908 (2019).

doi: 10.1016/j.stem.2019.04.014 pubmed: 31130512 pmcid: 6944064

Trujillo, C. A. et al. Complex oscillatory waves emerging from cortical organoids model early human brain network development. Cell Stem Cell 25, 558–569.e557 (2019).

doi: 10.1016/j.stem.2019.08.002 pubmed: 31474560 pmcid: 6778040

Passaro, A. P. & Stice, S. L. Electrophysiological analysis of brain organoids: current approaches and advancements. Front. Neurosci. 14, 622137 (2020).

doi: 10.3389/fnins.2020.622137 pubmed: 33510616

Samarasinghe, R. A. et al. Identification of neural oscillations and epileptiform changes in human brain organoids. Nat. Neurosci. 24, 1488–1500 (2021).

doi: 10.1038/s41593-021-00906-5 pubmed: 34426698 pmcid: 9070733

Windrem, M. S. et al. Human iPSC glial mouse chimeras reveal glial contributions to schizophrenia. Cell Stem Cell 21, 195–208.e196 (2017).

doi: 10.1016/j.stem.2017.06.012 pubmed: 28736215 pmcid: 5576346

Dong, X. et al. Human cerebral organoids establish subcortical projections in the mouse brain after transplantation. Mol. Psychiatry 26, 2964–2976 (2021).

doi: 10.1038/s41380-020-00910-4 pubmed: 33051604

Wilson, M. N. et al. Multimodal monitoring of human cortical organoids implanted in mice reveal functional connection with visual cortex. Nat. Commun. 13, 7945 (2022).

doi: 10.1038/s41467-022-35536-3 pubmed: 36572698 pmcid: 9792589

Cerneckis, J., Bu, G. & Shi, Y. Pushing the boundaries of brain organoids to study Alzheimer’s disease. Trends Mol. Med. 29, 659-672 (2023).

Dugger, B. N. & Dickson, D. W. Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 9, a028035 (2017).

doi: 10.1101/cshperspect.a028035 pubmed: 28062563 pmcid: 5495060

Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 3, 1–19 (2017).

Kalia, L. V. & Lang, A. E. Parkinson’s disease. Lancet 386, 896–912 (2015).

doi: 10.1016/S0140-6736(14)61393-3 pubmed: 25904081

Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Prim. 7, 33 (2021).

doi: 10.1038/s41572-021-00269-y pubmed: 33986301

Gonzales, M. M. et al. Biological aging processes underlying cognitive decline and neurodegenerative disease. J. Clin. Investig. 132, e158453 (2022).

doi: 10.1172/JCI158453 pubmed: 35575089 pmcid: 9106343

Camandola, S. & Mattson, M. P. Brain metabolism in health, aging, and neurodegeneration. Embo J. 36, 1474–1492 (2017).

doi: 10.15252/embj.201695810 pubmed: 28438892 pmcid: 5452017

Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of aging: an expanding universe. Cell 186, 243–278 (2023).

doi: 10.1016/j.cell.2022.11.001 pubmed: 36599349

Cornacchia, D. & Studer, L. Back and forth in time: directing age in iPSC-derived lineages. Brain Res. 1656, 14–26 (2017).

doi: 10.1016/j.brainres.2015.11.013 pubmed: 26592774

Studer, L., Vera, E. & Cornacchia, D. Programming and reprogramming cellular age in the era of induced pluripotency. Cell Stem Cell 16, 591–600 (2015).

doi: 10.1016/j.stem.2015.05.004 pubmed: 26046759 pmcid: 4508309

Mertens, J. et al. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer’s patients. Cell Stem Cell 28, 1533–1548.e1536 (2021).

doi: 10.1016/j.stem.2021.04.004 pubmed: 33910058 pmcid: 8423435

Miller, J. D. et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13, 691–705 (2013).

doi: 10.1016/j.stem.2013.11.006 pubmed: 24315443 pmcid: 4153390

Giacomelli, E. et al. Human stem cell models of neurodegeneration: from basic science of amyotrophic lateral sclerosis to clinical translation. Cell Stem Cell 29, 11–35 (2022).

doi: 10.1016/j.stem.2021.12.008 pubmed: 34995492 pmcid: 8785905

Okano, H. & Morimoto, S. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell 29, 189–208 (2022).

doi: 10.1016/j.stem.2022.01.007 pubmed: 35120619

Virdi, G. S. et al. Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons. Npj Parkinsons Dis. 8, 162 (2022).

doi: 10.1038/s41531-022-00423-7 pubmed: 36424392 pmcid: 9691718

Egawa, N. et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4, 145ra104 (2012).

doi: 10.1126/scitranslmed.3004052 pubmed: 22855461

Young, J. E. et al. Elucidating molecular phenotypes caused by the SORL1 Alzheimer’s disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell 16, 373–385 (2015).

doi: 10.1016/j.stem.2015.02.004 pubmed: 25772071 pmcid: 4388804

Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat. Genet. 53, 1276–1282 (2021).

doi: 10.1038/s41588-021-00921-z pubmed: 34493870 pmcid: 10243600

Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. & Bu, G. J. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat. Rev. Neurol. 15, 501–518 (2019).

doi: 10.1038/s41582-019-0228-7 pubmed: 31367008 pmcid: 7055192

Belloy, M. E., Napolioni, V. & Greicius, M. D. A quarter century of APOE and Alzheimer’s disease: progress to date and the path forward. Neuron 101, 820–838 (2019).

doi: 10.1016/j.neuron.2019.01.056 pubmed: 30844401 pmcid: 6407643

Serrano-Pozo, A., Das, S. & Hyman, B. T. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 20, 68–80 (2021).

doi: 10.1016/S1474-4422(20)30412-9 pubmed: 33340485 pmcid: 8096522

Sienski, G. et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. Sci. Transl. Med. 13, eaaz4564 (2021).

doi: 10.1126/scitranslmed.aaz4564 pubmed: 33658354 pmcid: 8218593

Tcw, J. et al. Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell 185, 2213–2233.e2225 (2022).

doi: 10.1016/j.cell.2022.05.017 pubmed: 35750033 pmcid: 9340815

Blanchard, J. W. et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature 611, 769–779 (2022).

doi: 10.1038/s41586-022-05439-w pubmed: 36385529 pmcid: 9870060

Murdock, M. H. & Tsai, L. H. Insights into Alzheimer’s disease from single-cell genomic approaches. Nat. Neurosci. 26, 181–195 (2023).

doi: 10.1038/s41593-022-01222-2 pubmed: 36593328 pmcid: 10155598

Victor, M. B. et al. Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity. Cell Stem Cell 29, 1197–1212.e1198 (2022).

doi: 10.1016/j.stem.2022.07.005 pubmed: 35931030 pmcid: 9623845

Chen, X. et al. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature 615, 668–677 (2023).

doi: 10.1038/s41586-023-05788-0 pubmed: 36890231 pmcid: 10258627

Gate, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature 577, 399–404 (2020).

doi: 10.1038/s41586-019-1895-7 pubmed: 31915375 pmcid: 7445078

Krauskopf, J. et al. Transcriptomics analysis of human iPSC-derived dopaminergic neurons reveals a novel model for sporadic Parkinson’s disease. Mol. Psychiatry 27, 4355–4367 (2022).

doi: 10.1038/s41380-022-01663-y pubmed: 35725899

Ryan, S. D. et al. Isogenic human iPSC parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1 alpha transcription. Cell 155, 1351–1364 (2013).

doi: 10.1016/j.cell.2013.11.009 pubmed: 24290359 pmcid: 4028128

Sommer, A. et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson’s disease. Cell Stem Cell 23, 123–131.e126 (2018).

doi: 10.1016/j.stem.2018.06.015 pubmed: 29979986

Baxi, E. G. et al. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nat. Neurosci. 25, 226–237 (2022).

doi: 10.1038/s41593-021-01006-0 pubmed: 35115730 pmcid: 8825283

Workman, M. J. et al. Large-scale differentiation of iPSC-derived motor neurons from ALS and control subjects. Neuron 111, 1191–1204.e1195 (2023).

doi: 10.1016/j.neuron.2023.01.010 pubmed: 36764301 pmcid: 10557526

Fujimori, K. et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 24, 1579–1589 (2018).

doi: 10.1038/s41591-018-0140-5 pubmed: 30127392

Chakrabarti, S. & Mohanakumar, K. P. Aging and neurodegeneration: a tangle of models and mechanisms. Aging Dis. 7, 111–113 (2016).

doi: 10.14336/AD.2016.0312 pubmed: 27114843 pmcid: 4809602

Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. & Santoro, A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576–590 (2018).

doi: 10.1038/s41574-018-0059-4 pubmed: 30046148

Franceschi, C., Garagnani, P., Vitale, G., Capri, M. & Salvioli, S. Inflammaging and ‘Garb-aging’. Trends Endocrinol. Metab. 28, 199–212 (2017).

doi: 10.1016/j.tem.2016.09.005 pubmed: 27789101

Grimm, A. & Eckert, A. Brain aging and neurodegeneration: from a mitochondrial point of view. J. Neurochem. 143, 418–431 (2017).

doi: 10.1111/jnc.14037 pubmed: 28397282 pmcid: 5724505

Bertucci, E. M. & Parrott, B. B. Is CpG density the link between epigenetic aging and lifespan? Trends Genet. 36, 725–727 (2020).

doi: 10.1016/j.tig.2020.06.003 pubmed: 32624337

Kosan, C., Heidel, F. H., Godmann, M. & Bierhoff, H. Epigenetic erosion in adult stem cells: drivers and passengers of aging. Cells 7, 237 (2018).

doi: 10.3390/cells7120237 pubmed: 30501028 pmcid: 6316114

Little, D. et al. A single cell high content assay detects mitochondrial dysfunction in iPSC-derived neurons with mutations in SNCA. Sci. Rep. 8, 9033 (2018).

doi: 10.1038/s41598-018-27058-0 pubmed: 29899557 pmcid: 5998042

Du, F., Yu, Q., Chen, A., Chen, D. & Yan, S. S. Astrocytes attenuate mitochondrial dysfunctions in human dopaminergic neurons derived from iPSC. Stem Cell Rep. 10, 366–374 (2018).

doi: 10.1016/j.stemcr.2017.12.021

Cheng, X. Y. et al. Human iPSCs derived astrocytes rescue rotenone-induced mitochondrial dysfunction and dopaminergic neurodegeneration in vitro by donating functional mitochondria. Transl. Neurodegener. 9, 1–14 (2020).

doi: 10.1186/s40035-020-00190-6

Zagoura, D., Canovas-Jorda, D., Pistollato, F., Bremer-Hoffmann, S. & Bal-Price, A. Evaluation of the rotenone-induced activation of the Nrf2 pathway in a neuronal model derived from human induced pluripotent stem cells. Neurochem. Int. 106, 62–73 (2017).

doi: 10.1016/j.neuint.2016.09.004 pubmed: 27615060

Benson, E. K., Lee, S. W. & Aaronson, S. A. Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence. J. Cell Sci. 123, 2605–2612 (2010).

doi: 10.1242/jcs.067306 pubmed: 20605919 pmcid: 2908049

Ambasudhan, R. et al. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem Cell 9, 113–118 (2011).

doi: 10.1016/j.stem.2011.07.002 pubmed: 21802386 pmcid: 4567246

Carter, J. L., Halmai, J. & Fink, K. D. The iNs and outs of direct reprogramming to induced neurons. Front. Genome Ed. 2, 7 (2020).

doi: 10.3389/fgeed.2020.00007 pubmed: 34713216 pmcid: 8525349

Drouin-Ouellet, J., Pircs, K., Barker, R. A., Jakobsson, J. & Parmar, M. Direct neuronal reprogramming for disease modeling studies using patient-derived neurons: what have we learned? Front. Neurosci. 11, 530 (2017).

doi: 10.3389/fnins.2017.00530 pubmed: 29033781 pmcid: 5625013

Mertens, J., Marchetto, M. C., Bardy, C. & Gage, F. H. Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience. Nat. Rev. Neurosci. 17, 424–437 (2016).

doi: 10.1038/nrn.2016.46 pubmed: 27194476 pmcid: 6276815

Wang, H., Yang, Y., Liu, J. & Qian, L. Direct cell reprogramming: approaches, mechanisms and progress. Nat. Rev. Mol. Cell Biol. 22, 410–424 (2021).

doi: 10.1038/s41580-021-00335-z pubmed: 33619373 pmcid: 8161510

Wapinski, O. L. et al. Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. Cell 155, 621–635 (2013).

doi: 10.1016/j.cell.2013.09.028 pubmed: 24243019

Herdy, J. R. et al. Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer’s disease. Cell Stem Cell 29, 1637–1652.e1636 (2022).

doi: 10.1016/j.stem.2022.11.010 pubmed: 36459967 pmcid: 10093780

Traxler, L. et al. Warburg-like metabolic transformation underlies neuronal degeneration in sporadic Alzheimer’s disease. Cell Metab. 34, 1248–1263.e1246 (2022).

doi: 10.1016/j.cmet.2022.07.014 pubmed: 35987203 pmcid: 9458870

Barisano, G. et al. Blood–brain barrier link to human cognitive impairment and Alzheimer’s disease. Nat. Cardiovasc. Res. 1, 108–115 (2022).

doi: 10.1038/s44161-021-00014-4 pubmed: 35450117 pmcid: 9017393

Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F. & O’Driscoll, C. M. The blood-brain barrier in aging and neurodegeneration. Mol. Psychiatr. 27, 2659–2673 (2022).

doi: 10.1038/s41380-022-01511-z

Montagne, A. et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296–302 (2015).

doi: 10.1016/j.neuron.2014.12.032 pubmed: 25611508 pmcid: 4350773

Sweeney, M. D., Sagare, A. P. & Zlokovic, B. V. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133–150 (2018).

doi: 10.1038/nrneurol.2017.188 pubmed: 29377008 pmcid: 5829048

Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat. Rev. Neurosci. 12, 723–738 (2011).

doi: 10.1038/nrn3114 pubmed: 22048062 pmcid: 4036520

Chen, X. et al. Modeling sporadic Alzheimer’s disease in human brain organoids under serum exposure. Adv. Sci. 8, e2101462 (2021).

doi: 10.1002/advs.202101462

Mirabelli, P., Coppola, L. & Salvatore, M. Cancer cell lines are useful model systems for medical research. Cancers 11, 1098 (2019).

doi: 10.3390/cancers11081098 pubmed: 31374935 pmcid: 6721418

Gillet, J. P., Varma, S. & Gottesman, M. M. The clinical relevance of cancer cell lines. J. Natl. Cancer Inst. 105, 452–458 (2013).

doi: 10.1093/jnci/djt007 pubmed: 23434901 pmcid: 3691946

Wilding, J. L. & Bodmer, W. F. Cancer cell lines for drug discovery and development. Cancer Res. 74, 2377–2384 (2014).

doi: 10.1158/0008-5472.CAN-13-2971 pubmed: 24717177

Wijewardhane, N., Dressler, L. & Ciccarelli, F. D. Normal somatic mutations in cancer transformation. Cancer Cell 39, 125–129 (2021).

doi: 10.1016/j.ccell.2020.11.002 pubmed: 33220180

Smith, R. C. & Tabar, V. Constructing and deconstructing cancers using human pluripotent stem cells and organoids. Cell Stem Cell 24, 12–24 (2019).

doi: 10.1016/j.stem.2018.11.012 pubmed: 30581078

Haag, D. et al. H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model. Cancer Cell 39, 407–422.e413 (2021).

doi: 10.1016/j.ccell.2021.01.005 pubmed: 33545065

Crespo, M. et al. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat. Med. 23, 878–884 (2017).

doi: 10.1038/nm.4355 pubmed: 28628110 pmcid: 6055224

Ford, A. C., Yuan, Y. & Moayyedi, P. Long-term impact of helicobacter pylori eradication therapy on gastric cancer incidence and mortality in healthy infected individuals: a meta-analysis beyond 10 years of follow-up. Gastroenterology 163, 754–756.e751 (2022).

doi: 10.1053/j.gastro.2022.05.027 pubmed: 35598628

Polk, D. B. & Peek, R. M. Jr. Helicobacter pylori: gastric cancer and beyond. Nat. Rev. Cancer 10, 403–414 (2010).

doi: 10.1038/nrc2857 pubmed: 20495574 pmcid: 2957472

McCracken, K. W. et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 516, 400–404 (2014).

doi: 10.1038/nature13863 pubmed: 25363776 pmcid: 4270898

Wang, T. et al. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell 28, 1074–1089.e1077 (2021).

doi: 10.1016/j.stem.2021.01.011 pubmed: 33571445 pmcid: 8178190

Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816–818 (2016).

doi: 10.1126/science.aaf6116 pubmed: 27064148

Scoon, W. A. et al. Ebola virus infection induces a delayed type I IFN response in bystander cells and the shutdown of key liver genes in human iPSC-derived hepatocytes. Stem Cell Rep. 17, 2286–2302 (2022).

doi: 10.1016/j.stemcr.2022.08.003

Luo, Y., Zhang, M., Chen, Y., Chen, Y. & Zhu, D. Application of human induced pluripotent stem cell-derived cellular and organoid models for COVID-19 research. Front. Cell Dev. Biol. 9, 720099 (2021).

doi: 10.3389/fcell.2021.720099 pubmed: 34552930 pmcid: 8450444

Harschnitz, O. & Studer, L. Human stem cell models to study host-virus interactions in the central nervous system. Nat. Rev. Immunol. 21, 441–453 (2021).

doi: 10.1038/s41577-020-00474-y pubmed: 33398129 pmcid: 9653304

Lamers, M. M. & Haagmans, B. L. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol 20, 270–284 (2022).

doi: 10.1038/s41579-022-00713-0 pubmed: 35354968

Cevik, M., Kuppalli, K., Kindrachuk, J. & Peiris, M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 371, m3862 (2020).

doi: 10.1136/bmj.m3862 pubmed: 33097561

Harrison, A. G., Lin, T. & Wang, P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 41, 1100–1115 (2020).

doi: 10.1016/j.it.2020.10.004 pubmed: 33132005 pmcid: 7556779

Bestion, E., Halfon, P., Mezouar, S. & Mege, J. L. Cell and animal models for SARS-CoV-2 research. Viruses 14, 1507 (2022).

doi: 10.3390/v14071507 pubmed: 35891487 pmcid: 9319816

Chu, H., Chan, J. F. & Yuen, K. Y. Animal models in SARS-CoV-2 research. Nat. Methods 19, 392–394 (2022).

doi: 10.1038/s41592-022-01447-w pubmed: 35396468

Cleary, S. J. et al. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. Br. J. Pharm. 177, 4851–4865 (2020).

doi: 10.1111/bph.15143

Lee, C. Y. & Lowen, A. C. Animal models for SARS-CoV-2. Curr. Opin. Virol. 48, 73–81 (2021).

doi: 10.1016/j.coviro.2021.03.009 pubmed: 33906125 pmcid: 8023231

Takayama, K. In vitro and animal models for SARS-CoV-2 research. Trends Pharm. Sci. 41, 513–517 (2020).

doi: 10.1016/j.tips.2020.05.005 pubmed: 32553545

Simoneau, C. R. & Ott, M. Modeling multi-organ infection by SARS-CoV-2 using stem cell technology. Cell Stem Cell 27, 859–868 (2020).

doi: 10.1016/j.stem.2020.11.012 pubmed: 33275899 pmcid: 7713543

Huang, J. et al. SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar Type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. Cell Stem Cell 27, 962–973.e967 (2020).

doi: 10.1016/j.stem.2020.09.013 pubmed: 32979316 pmcid: 7500949

Lian, Q. et al. Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model. Nat. Commun. 13, 2028 (2022).

doi: 10.1038/s41467-022-29731-5 pubmed: 35440562 pmcid: 9018716

Elrobaa, I. H. & New, K. J. COVID-19: pulmonary and extra pulmonary manifestations. Front. Public Health 9, 711616 (2021).

doi: 10.3389/fpubh.2021.711616 pubmed: 34650947 pmcid: 8505777

Gupta, A. et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 26, 1017–1032 (2020).

doi: 10.1038/s41591-020-0968-3 pubmed: 32651579

Ning, Q. et al. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal. Transduct. Target Ther. 7, 57 (2022).

doi: 10.1038/s41392-022-00907-1 pubmed: 35197452 pmcid: 8863906

Chen, K. G., Park, K. & Spence, J. R. Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids. Nat. Cell Biol. 23, 822–833 (2021).

doi: 10.1038/s41556-021-00721-x pubmed: 34341531 pmcid: 8355201

Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181, 905–913.e907 (2020).

doi: 10.1016/j.cell.2020.04.004 pubmed: 32333836 pmcid: 7181998

Wang, W. L. et al. Detection of SARS-CoV-2 in different types of clinical specimens. Jama 323, 1843–1844 (2020).

pubmed: 32159775 pmcid: 7066521

Bojkova, D. et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovasc. Res. 116, 2207–2215 (2020).

doi: 10.1093/cvr/cvaa267 pubmed: 32966582

Perez-Bermejo, J. A. et al. SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19. Sci. Transl. Med. 13, eabf7872 (2021).

doi: 10.1126/scitranslmed.abf7872 pubmed: 33723017

Sharma, A. et al. Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Rep. Med. 1, 100052 (2020).

doi: 10.1016/j.xcrm.2020.100052 pubmed: 32835305 pmcid: 7323681

Ahmad, I. & Rathore, F. A. Neurological manifestations and complications of COVID-19: a literature review. J. Clin. Neurosci. 77, 8–12 (2020).

doi: 10.1016/j.jocn.2020.05.017 pubmed: 32409215 pmcid: 7200361

Niazkar, H. R., Zibaee, B., Nasimi, A. & Bahri, N. The neurological manifestations of COVID-19: a review article. Neurol. Sci. 41, 1667–1671 (2020).

doi: 10.1007/s10072-020-04486-3 pubmed: 32483687 pmcid: 7262683

Yassin, A. et al. Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. BMC Neurol. 21, 1–17 (2021).

doi: 10.1186/s12883-021-02161-4

Ramani, A. et al. SARS-CoV-2 targets neurons of 3D human brain organoids. Embo J. 39, e106230 (2020).

doi: 10.15252/embj.2020106230 pubmed: 32876341 pmcid: 7560208

Zhang, B. Z. et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 30, 928–931 (2020).

doi: 10.1038/s41422-020-0390-x pubmed: 32753756

Cui, Q. et al. Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection. iScience 25, 103684 (2022).

doi: 10.1016/j.isci.2021.103684 pubmed: 34977495

Wang, C. et al. ApoE-isoform-dependent SARS-CoV-2 neurotropism and cellular response. Cell Stem Cell 28, 331–342.e335 (2021).

doi: 10.1016/j.stem.2020.12.018 pubmed: 33450186 pmcid: 7832490

Shen, W. B. et al. SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer’s-like neuropathology. Preprint at BioRxiv (2022).

Kleiman, R. J. & Engle, S. J. Human inducible pluripotent stem cells: Realization of initial promise in drug discovery. Cell Stem Cell 28, 1507–1515 (2021).

doi: 10.1016/j.stem.2021.08.002 pubmed: 34478628

Gu, M. et al. iPSC-endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension. Sci. Transl. Med. 13, eaba6480 (2021).

doi: 10.1126/scitranslmed.aba6480 pubmed: 33952674 pmcid: 8762958

Bray, M. A. et al. Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat. Protoc. 11, 1757–1774 (2016).

doi: 10.1038/nprot.2016.105 pubmed: 27560178 pmcid: 5223290

Chin, M. Y., Espinosa, J. A., Pohan, G., Markossian, S. & Arkin, M. R. Reimagining dots and dashes: visualizing structure and function of organelles for high-content imaging analysis. Cell Chem. Biol. 28, 320–337 (2021).

doi: 10.1016/j.chembiol.2021.01.016 pubmed: 33600764 pmcid: 7995685

Vamathevan, J. et al. Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. 18, 463–477 (2019).

doi: 10.1038/s41573-019-0024-5 pubmed: 30976107 pmcid: 6552674

Taubes, A. et al. Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease. Nat. Aging 1, 932–947 (2021).

doi: 10.1038/s43587-021-00122-7 pubmed: 36172600 pmcid: 9514594

Theodoris, C. V. et al. Network-based screen in iPSC-derived cells reveals therapeutic candidate for heart valve disease. Science 371, eabd0724 (2021).

doi: 10.1126/science.abd0724 pubmed: 33303684

Pangalos, M. N., Schechter, L. E. & Hurko, O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6, 521–532 (2007).

doi: 10.1038/nrd2094 pubmed: 17599084

Waring, M. J. et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14, 475–486 (2015).

doi: 10.1038/nrd4609 pubmed: 26091267

Inoue, H. & Yamanaka, S. The use of induced pluripotent stem cells in drug development. Clin. Pharm. Ther. 89, 655–661 (2011).

doi: 10.1038/clpt.2011.38

Liu, W., Deng, Y., Liu, Y., Gong, W. & Deng, W. Stem cell models for drug discovery and toxicology studies. J. Biochem. Mol. Toxicol. 27, 17–27 (2013).

doi: 10.1002/jbt.21470 pubmed: 23293059

Pasteuning-Vuhman, S., de Jongh, R., Timmers, A. & Pasterkamp, R. J. Towards advanced iPSC-based drug development for neurodegenerative disease. Trends Mol. Med. 27, 263–279 (2021).

doi: 10.1016/j.molmed.2020.09.013 pubmed: 33121873

Reiser, J. & Sever, S. Podocyte biology and pathogenesis of kidney disease. Annu Rev. Med. 64, 357–366 (2013).

doi: 10.1146/annurev-med-050311-163340 pubmed: 23190150

Musah, S. et al. Mature induced-pluripotent-stem-cell-derived human podocytes reconstitute kidney glomerular-capillary-wall function on a chip. Nat. Biomed. Eng. 1, 0069 (2017).

doi: 10.1038/s41551-017-0069 pubmed: 29038743 pmcid: 5639718

Richards, D. J. et al. Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity. Nat. Biomed. Eng. 4, 446–462 (2020).

doi: 10.1038/s41551-020-0539-4 pubmed: 32284552 pmcid: 7422941

Matsa, E. et al. Transcriptome profiling of patient-specific human iPSC-cardiomyocytes predicts individual drug safety and efficacy responses in vitro. Cell Stem Cell 19, 311–325 (2016).

doi: 10.1016/j.stem.2016.07.006 pubmed: 27545504 pmcid: 5087997

Sharma, A. et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci. Transl. Med. 9, eaaf2584 (2017).

doi: 10.1126/scitranslmed.aaf2584 pubmed: 28202772 pmcid: 5409837

Pellegrini, L. et al. Human CNS barrier-forming organoids with cerebrospinal fluid production. Science 369, eaaz5626 (2020).

doi: 10.1126/science.aaz5626 pubmed: 32527923 pmcid: 7116154

Kwon, O. et al. The development of a functional human small intestinal epithelium model for drug absorption. Sci. Adv. 7, eabh1586 (2021).

doi: 10.1126/sciadv.abh1586 pubmed: 34078609

Westerling-Bui, A. D. et al. Transplanted organoids empower human preclinical assessment of drug candidate for the clinic. Sci. Adv. 8, eabj5633 (2022).

doi: 10.1126/sciadv.abj5633 pubmed: 35857479 pmcid: 9258952

Brown, C. et al. Mesenchymal stem cells: cell therapy and regeneration potential. J. Tissue Eng. Regen. Med. 13, 1738–1755 (2019).

doi: 10.1002/term.2914 pubmed: 31216380

Chien, K. R. et al. Regenerating the field of cardiovascular cell therapy. Nat. Biotechnol. 37, 232–237 (2019).

doi: 10.1038/s41587-019-0042-1 pubmed: 30778231

Huang, K., Hu, S. & Cheng, K. A new era of cardiac cell therapy: opportunities and challenges. Adv. Health. Mater. 8, e1801011 (2019).

doi: 10.1002/adhm.201801011

Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).

doi: 10.1038/s41408-021-00459-7 pubmed: 33824268 pmcid: 8024391

Brown, C. E. & Mackall, C. L. CAR T cell therapy: inroads to response and resistance. Nat. Rev. Immunol. 19, 73–74 (2019).

doi: 10.1038/s41577-018-0119-y pubmed: 30631206

Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G. & June, C. H. Engineered cellular immunotherapies in cancer and beyond. Nat. Med. 28, 678–689 (2022).

doi: 10.1038/s41591-022-01765-8 pubmed: 35440724 pmcid: 9305718

Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M. & Veiseh, O. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. 21, 655–675 (2022).

doi: 10.1038/s41573-022-00476-6 pubmed: 35637318 pmcid: 9149674

Desgres, M. & Menasche, P. Clinical translation of pluripotent stem cell therapies: challenges and considerations. Cell Stem Cell 25, 594–606 (2019).

doi: 10.1016/j.stem.2019.10.001 pubmed: 31703770

Stevens, K. R. & Murry, C. E. Human pluripotent stem cell-derived engineered tissues: clinical considerations. Cell Stem Cell 22, 294–297 (2018).

doi: 10.1016/j.stem.2018.01.015 pubmed: 29499147 pmcid: 6344123

Doss, M. X. & Sachinidis, A. Current challenges of iPSC-based disease modeling and therapeutic implications. Cells 8, 403 (2019).

doi: 10.3390/cells8050403 pubmed: 31052294 pmcid: 6562607

Lovell-Badge, R. et al. ISSCR guidelines for stem cell research and clinical translation: the 2021 update. Stem Cell Rep. 16, 1398–1408 (2021).

doi: 10.1016/j.stemcr.2021.05.012

Balboa, D. et al. Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol. 40, 1042–1055 (2022).

doi: 10.1038/s41587-022-01219-z pubmed: 35241836 pmcid: 9287162

Du, Y. et al. Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates. Nat. Med. 28, 272–282 (2022).

doi: 10.1038/s41591-021-01645-7 pubmed: 35115708

Feng, L. et al. Developing hypoimmunogenic human iPSC-derived oligodendrocyte progenitor cells as an off-the-shelf cell therapy for myelin disorders. Adv. Sci. 10, e2206910 (2023).

Madrid, M., Sumen, C., Aivio, S. & Saklayen, N. Autologous induced pluripotent stem cell-based cell therapies: promise, progress, and challenges. Curr. Protoc. 1, e88 (2021).

doi: 10.1002/cpz1.88 pubmed: 33725407

Schweitzer, J. S. et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. N. Engl. J. Med. 382, 1926–1932 (2020).

doi: 10.1056/NEJMoa1915872 pubmed: 32402162 pmcid: 7288982

Schweitzer, J. S., Song, B. & Kim, K. S. A step closer to autologous cell therapy for Parkinson’s disease. Cell Stem Cell 28, 595–597 (2021).

doi: 10.1016/j.stem.2021.03.010 pubmed: 33798419

Tang, L. V. et al. Gene editing of human iPSCs rescues thrombophilia in hereditary antithrombin deficiency in mice. Sci. Transl. Med. 14, eabq3202 (2022).

doi: 10.1126/scitranslmed.abq3202 pubmed: 36449603

Maxwell, K. G. et al. Gene-edited human stem cell-derived beta cells from a patient with monogenic diabetes reverse preexisting diabetes in mice. Sci. Transl. Med. 12, eaax9106 (2020).

doi: 10.1126/scitranslmed.aax9106 pubmed: 32321868 pmcid: 7233417

Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185–199 (2020).

doi: 10.1038/s41573-019-0051-2 pubmed: 31900462

Crow, D. Could iPSCs enable “off-the-shelf” cell therapy? Cell 177, 1667–1669 (2019).

doi: 10.1016/j.cell.2019.05.043 pubmed: 31199910

Lanza, R., Russell, D. W. & Nagy, A. Engineering universal cells that evade immune detection. Nat. Rev. Immunol. 19, 723–733 (2019).

doi: 10.1038/s41577-019-0200-1 pubmed: 31417198

Wang, B. et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat. Biomed. Eng. 5, 429–440 (2021).

doi: 10.1038/s41551-021-00730-z pubmed: 34002062

Hu, X. et al. Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat. Biotechnol. 42, 413–423 (2023).

Alvarez-Palomo, B. et al. Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells. Stem Cell Res Ther. 12, 233 (2021).

doi: 10.1186/s13287-021-02301-0 pubmed: 33849662 pmcid: 8042859

Lee, S. et al. Repurposing the cord blood bank for haplobanking of HLA-Homozygous iPSCs and their usefulness to multiple populations. Stem Cells 36, 1552–1566 (2018).

doi: 10.1002/stem.2865 pubmed: 30004605

Sullivan, S. et al. Haplobanking induced pluripotent stem cells for clinical use. Stem Cell Res. 49, 102035 (2020).

doi: 10.1016/j.scr.2020.102035 pubmed: 33221677

Yoshida, S. et al. A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population. Med 4, 51–66.e10 (2023).

doi: 10.1016/j.medj.2022.10.003 pubmed: 36395757

Nguyen, P. K., Neofytou, E., Rhee, J.-W. & Wu, J. C. Potential strategies to address the major clinical barriers facing stem cell regenerative therapy for cardiovascular disease: a review. JAMA Cardiol. 1, 953–962 (2016).

doi: 10.1001/jamacardio.2016.2750 pubmed: 27579998 pmcid: 5378463

Aijaz, A. et al. Biomanufacturing for clinically advanced cell therapies. Nat. Biomed. Eng. 2, 362–376 (2018).

doi: 10.1038/s41551-018-0246-6 pubmed: 31011198 pmcid: 6594100

Lee, A. S., Tang, C., Rao, M. S., Weissman, I. L. & Wu, J. C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19, 998–1004 (2013).

doi: 10.1038/nm.3267 pubmed: 23921754 pmcid: 3967018

Chour, T. et al. Method for selective ablation of undifferentiated human pluripotent stem cell populations for cell-based therapies. JCI Insight 6, e142000 (2021).

doi: 10.1172/jci.insight.142000 pubmed: 33830086 pmcid: 8119193

Kuang, Y. et al. Efficient, selective removal of human pluripotent stem cells via ecto-alkaline phosphatase-mediated aggregation of synthetic peptides. Cell Chem. Biol. 24, 685–694.e684 (2017).

doi: 10.1016/j.chembiol.2017.04.010 pubmed: 28529132

Jones, B. S., Lamb, L. S., Goldman, F. & Di Stasi, A. Improving the safety of cell therapy products by suicide gene transfer. Front. Pharm. 5, 254 (2014).

doi: 10.3389/fphar.2014.00254

Lund, R. J., Narva, E. & Lahesmaa, R. Genetic and epigenetic stability of human pluripotent stem cells. Nat. Rev. Genet. 13, 732–744 (2012).

doi: 10.1038/nrg3271 pubmed: 22965355

Ma, H. et al. Abnormalities in human pluripotent cells due to reprogramming mechanisms. Nature 511, 177–183 (2014).

doi: 10.1038/nature13551 pubmed: 25008523 pmcid: 4898064

Guo, R. et al. Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells. Exp. Hematol. Oncol. 11, 1–17 (2022).

doi: 10.1186/s40164-022-00285-y

Motazedian, A. et al. Multipotent RAG1+ progenitors emerge directly from haemogenic endothelium in human pluripotent stem cell-derived haematopoietic organoids. Nat. Cell Biol. 22, 60–73 (2020).

doi: 10.1038/s41556-019-0445-8 pubmed: 31907413

Seet, C. S. et al. Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids. Nat. Methods 14, 521–530 (2017).

doi: 10.1038/nmeth.4237 pubmed: 28369043 pmcid: 5426913

Wang, Z. et al. 3D-organoid culture supports differentiation of human CAR(+) iPSCs into highly functional CAR T cells. Cell Stem Cell 29, 651–653 (2022).

doi: 10.1016/j.stem.2022.03.007 pubmed: 35395190

Nagamoto, Y. et al. Transplantation of a human iPSC-derived hepatocyte sheet increases survival in mice with acute liver failure. J. Hepatol. 64, 1068–1075 (2016).

doi: 10.1016/j.jhep.2016.01.004 pubmed: 26778754

Sharma, R. et al. Clinical-grade stem cell-derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs. Sci. Transl. Med. 11, eaat5580 (2019).

doi: 10.1126/scitranslmed.aat5580 pubmed: 30651323 pmcid: 8784963

Glaeser, J. D. et al. iPSC-neural crest derived cells embedded in 3D printable bio-ink promote cranial bone defect repair. Sci. Rep. 12, 18701 (2022).

doi: 10.1038/s41598-022-22502-8 pubmed: 36333414 pmcid: 9636385

Cichocki, F. et al. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. Sci. Transl. Med. 12, eaaz5618 (2020).

doi: 10.1126/scitranslmed.aaz5618 pubmed: 33148626 pmcid: 8861807

Moriarty, N. et al. A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells. Cell Stem Cell 29, 434–448.e435 (2022).

doi: 10.1016/j.stem.2022.01.013 pubmed: 35180398

Iancu, E. M. & Kandalaft, L. E. Challenges and advantages of cell therapy manufacturing under good manufacturing practices within the hospital setting. Curr. Opin. Biotechnol. 65, 233–241 (2020).

doi: 10.1016/j.copbio.2020.05.005 pubmed: 32663771

Ackermann, M. et al. Continuous human iPSC-macrophage mass production by suspension culture in stirred tank bioreactors. Nat. Protoc. 17, 513–539 (2022).

doi: 10.1038/s41596-021-00654-7 pubmed: 35039668 pmcid: 7612500

Ackermann, M. et al. Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections. Nat. Commun. 9, 5088 (2018).

doi: 10.1038/s41467-018-07570-7 pubmed: 30504915 pmcid: 6269475

Yasuda, S. Y. et al. Chemically defined and growth-factor-free culture system for the expansion and derivation of human pluripotent stem cells. Nat. Biomed. Eng. 2, 173–182 (2018).

doi: 10.1038/s41551-018-0200-7 pubmed: 31015717

Zhao, Z. et al. Organoids. Nat. Rev. Methods Prim. 2, 94 (2022).

doi: 10.1038/s43586-022-00174-y

Basu, S. et al. Live-cell three-dimensional single-molecule tracking reveals modulation of enhancer dynamics by NuRD. Nat. Struct. Mol. Biol. 30, 1628–1639 (2023).

Dodonova, S. O., Zhu, F., Dienemann, C., Taipale, J. & Cramer, P. Nucleosome-bound SOX2 and SOX11 structures elucidate pioneer factor function. Nature 580, 669–672 (2020).

doi: 10.1038/s41586-020-2195-y pubmed: 32350470

Wang, J. et al. Phase separation of OCT4 controls TAD reorganization to promote cell fate transitions. Cell Stem Cell 28, 1868–1883.e1811 (2021).

doi: 10.1016/j.stem.2021.04.023 pubmed: 34038708

He, W. et al. De novo identification of essential protein domains from CRISPR-Cas9 tiling-sgRNA knockout screens. Nat. Commun. 10, 4541 (2019).

doi: 10.1038/s41467-019-12489-8 pubmed: 31586052 pmcid: 6778102

Hsu, J. Y. et al. CRISPR-SURF: discovering regulatory elements by deconvolution of CRISPR tiling screen data. Nat. Methods 15, 992–993 (2018).

doi: 10.1038/s41592-018-0225-6 pubmed: 30504875 pmcid: 6620603

Yang, L. et al. High-resolution characterization of gene function using single-cell CRISPR tiling screen. Nat. Commun. 12, 4063 (2021).

doi: 10.1038/s41467-021-24324-0 pubmed: 34210975 pmcid: 8249386

Liu, P., Chen, M., Liu, Y., Qi, L. S. & Ding, S. CRISPR-based chromatin remodeling of the endogenous Oct4 or Sox2 Locus enables reprogramming to pluripotency. Cell Stem Cell 22, 252–261.e254 (2018).

doi: 10.1016/j.stem.2017.12.001 pubmed: 29358044

Baumann, V. et al. Targeted removal of epigenetic barriers during transcriptional reprogramming. Nat. Commun. 10, 2119 (2019).

doi: 10.1038/s41467-019-10146-8 pubmed: 31073172 pmcid: 6509258

Takahashi, Y. et al. Transgenerational inheritance of acquired epigenetic signatures at CpG islands in mice. Cell 186, 715–731.e719 (2023).

doi: 10.1016/j.cell.2022.12.047 pubmed: 36754048

Tompkins, J. et al. Engineering CpG island DNA methylation in pluripotent cells through synthetic CpG-free ssDNA insertion. Cell Rep. Methods 3, 100465 (2023).

doi: 10.1016/j.crmeth.2023.100465 pubmed: 37323577 pmcid: 10261899

Cerneckis, J., Ming, G. L., Song, H., He, C. & Shi, Y. The rise of epitranscriptomics: recent developments and future directions. Trends Pharm. Sci. 45, 24–38 (2024).

doi: 10.1016/j.tips.2023.11.002 pubmed: 38103979

Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).

doi: 10.1038/s41586-021-03819-2 pubmed: 34265844 pmcid: 8371605

Stahl, K., Graziadei, A., Dau, T., Brock, O. & Rappsilber, J. Protein structure prediction with in-cell photo-crosslinking mass spectrometry and deep learning. Nat. Biotechnol. 1−10 (2023).

Greener, J. G., Kandathil, S. M., Moffat, L. & Jones, D. T. A guide to machine learning for biologists. Nat. Rev. Mol. Cell Biol. 23, 40–55 (2022).

doi: 10.1038/s41580-021-00407-0 pubmed: 34518686

Coronnello, C. & Francipane, M. G. Moving towards induced pluripotent stem cell-based therapies with artificial intelligence and machine learning. Stem Cell Rev. Rep. 18, 559–569 (2022).

doi: 10.1007/s12015-021-10302-y pubmed: 34843066

Pantazis, C. B. et al. A reference human induced pluripotent stem cell line for large-scale collaborative studies. Cell Stem Cell 29, 1685–1702.e1622 (2022).

doi: 10.1016/j.stem.2022.11.004 pubmed: 36459969 pmcid: 9782786

Bisogno, L. S. et al. Ancestry-dependent gene expression correlates with reprogramming to pluripotency and multiple dynamic biological processes. Sci. Adv. 6, eabc3851 (2020).

doi: 10.1126/sciadv.abc3851 pubmed: 33219026 pmcid: 7679169

Czerniecki, S. M. et al. High-throughput screening enhances kidney organoid differentiation from human pluripotent stem cells and enables automated multidimensional phenotyping. Cell Stem Cell 22, 929–940.e924 (2018).

doi: 10.1016/j.stem.2018.04.022 pubmed: 29779890 pmcid: 5984728

Lu, Y., Zhou, Y., Ju, R. & Chen, J. Human-animal chimeras for autologous organ transplantation: technological advances and future perspectives. Ann. Transl. Med. 7, 576 (2019).

doi: 10.21037/atm.2019.10.13 pubmed: 31807557 pmcid: 6861770

Takebe, T. et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499, 481–484 (2013).

doi: 10.1038/nature12271 pubmed: 23823721

Suchy, F., Yamaguchi, T. & Nakauchi, H. iPSC-derived organs in vivo: challenges and promise. Cell Stem Cell 22, 21–24 (2018).

doi: 10.1016/j.stem.2017.12.003 pubmed: 29304339

Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Subventions

Informations de copyright

Références

Auteurs

Jonas Cerneckis (J)

Hongxia Cai (H)

Yanhong Shi (Y)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH